ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0006600;creatine metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;151.3209695708494;7.474488534686424;0.005064576671505272;0.7572456912631272;[GHR]
GO:0003333;amino acid transmembrane transport;9.0;0.5756379274792419;0.68405958891991;8.302854513188667;195.84914281057607;5.500407508664414;0.006554894557084751;0.6775317209684948;[SLC1A3, SLC38A11, SLC7A11, SLC38A6, SLC17A6, SLC36A1, SLC6A16, SLC6A15, SLC6A6, SLC7A7, SLC7A8]
GO:0002244;hematopoietic progenitor cell differentiation;4.0;0.811012628672052;0.655506314336026;8.935377071932177;21.066225782797595;5.395046993006588;7.050676185779127E-4;0.5259029541176994;[TNFRSF13B, ESCO2, PLD4, JAM3, TGFB1, ACE, INHBA]
GO:0071373;cellular response to luteinizing hormone stimulus;8.0;1.0;0.875;9.628524252492122;601.1788189541068;8.67846133901236;0.020120914044583264;0.8188169164668168;[LHCGR]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, GHR, PROK2, MAP4K1, MAP2K2, DUSP6, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, DRD4, EGF, CSPG4, PKN1]
GO:0050796;regulation of insulin secretion;9.0;0.8259837884571596;0.8092325194088689;9.533214072687796;205.48125160941495;4.61801832846594;0.006877272570246766;0.6324062972578516;[KCNG2, GHSR, BLK, CNR1]
GO:0002237;response to molecule of bacterial origin;4.0;0.6873818243518346;0.5936909121759173;8.741221057491218;31.746667436368902;4.018171853803189;0.0010625323889495053;0.45548949546759565;[EDNRB, MEF2C, SLC11A1, SLPI, ABCB4, MGST1, ELANE, ABCA1, FZD5, CD24, CTSG, CD36, ARG1, PDCD1LG2, TLR1, TLR4, TLR2, PTGS2, NR1H2, LILRB1, LILRB2, PYCARD, GHSR, CD180, F2R, KMO, ADAM9, S100A8, CD274, C5AR1, LY96, CSF2RB, TNFRSF11A, STAP1, NLRP3, DEFA4, TNFRSF10C, TNFRSF10B, DEFA1, SELE, ALPL, HMGB2, CXCL1, TREM2, CXCL2, PTGIR, TNFRSF1B, CEBPE, CNR1, LTBR, FCGR2B]
GO:0000186;activation of MAPKK activity;13.0;0.8259837884571596;0.8755468589962163;9.54300207905396;3706.2450018205795;5.845247994956144;0.12404468480698592;0.7614812190615239;[LRRK2, EGF, F2R, ADAM9]
GO:0048246;macrophage chemotaxis;8.0;1.0;0.875;9.628524252492122;95.91852822164125;7.212124270218933;0.0032103068185073717;0.7438283705770736;[LGALS3, EDNRB, NUP85, AZU1]
GO:0048488;synaptic vesicle endocytosis;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;55.00680757199006;6.599019797332524;0.0018410283465216937;0.6605944919115335;[NLGN4Y, NLGN1, SYT2]
GO:0006958;complement activation, classical pathway;8.0;1.0;0.875;9.628524252492122;171.02669507306572;4.7081694254602375;0.005724109570062889;0.6157760033703056;[, IGHM, CR2, CR1, IGHG1, IGKC, IGLV1-44, IGHD, IGHA1, IGKV3-20]
GO:0060474;positive regulation of flagellated sperm motility involved in capacitation;8.0;1.0;0.875;9.628524252492122;162.69194750477402;8.67846133901236;0.005445153069737985;0.8188169164668168;[CCR6]
GO:0060113;inner ear receptor cell differentiation;6.0;0.8653626801206646;0.7558016526504768;9.271849308553389;24.937426793704354;7.474488534686424;8.346332325582432E-4;0.7053660038532718;[JAG1, USH2A]
GO:1902564;negative regulation of neutrophil activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.92306413003195;8.390779266560578;0.00424800073309046;0.7800242071602487;[FCGR2B]
GO:1904861;excitatory synapse assembly;5.0;1.0;0.7902410118609202;9.628524252492122;37.238733880868345;8.16763571524637;0.0012463469103079984;0.7079342821725234;[NLGN1]
GO:0048009;insulin-like growth factor receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.138016298065211;0.0010376185600805164;0.7400384854347593;[GHR, CRIM1, AKT1, TSC2]
GO:1900024;regulation of substrate adhesion-dependent cell spreading;7.0;0.8933024483968273;0.7975705894556142;9.485423408851448;77.8386910509756;5.905872616772578;0.002605190939202256;0.6529459655301135;[DOCK5, NRP1, TACSTD2, PDPN, FLNA, ACTN4, OLFM4, PTK2, DNM2]
GO:0060119;inner ear receptor cell development;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;34.232648149996464;7.069023426578259;0.0011457359261972313;0.6517511986393402;[SLC4A7, GABRA5]
GO:1903413;cellular response to bile acid;6.0;1.0;0.8231203125901445;9.628524252492122;286.3546574774815;8.67846133901236;0.009584032683311037;0.7669372290569613;[ABCB4]
GO:1900029;positive regulation of ruffle assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;7.138016298065211;0.006704083591926775;0.7612791106150483;[CYFIP1, NLGN1, EPS8L1, PFN1]
GO:1903416;response to glycoside;4.0;0.7866048967936545;0.6433024483968273;8.840066892127851;27.321196622860832;8.16763571524637;9.144158634865458E-4;0.6676932703116032;[ABCB4]
GO:1903779;regulation of cardiac conduction;7.0;0.6913464685778243;0.6965925995461126;8.763526815005518;28.828680454715183;5.788089581116195;9.648699906913433E-4;0.6469225356091749;[ATP2A3, SLC8A1, FLNA, CXADR, CAV1, TRPC1]
GO:0042700;luteinizing hormone signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;8.67846133901236;9.028936615729279E-4;0.7669372290569613;[LHCGR]
GO:0048496;maintenance of animal organ identity;6.0;0.9326813400603323;0.7894609826203107;9.533214072687796;86.47711930152906;8.16763571524637;0.002894311358667591;0.7408135829017477;[GPR98, USH2A]
GO:0005513;detection of calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;27.95353479882516;7.212124270218933;9.355796531686605E-4;0.6919486831672181;[KCNMB3]
GO:0051412;response to corticosterone;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;159.4387911184404;6.7325511899570465;0.0053362728531380675;0.719302980950052;[CDKN1A, AVPR1A]
GO:0006605;protein targeting;9.0;0.7192862368539868;0.7558837436072825;9.182237149863703;93.4429707305496;4.015022244900292;0.0031274521371376313;0.6015690495021188;[SCARB2, LAMP2, HGS, SLC27A2, NUP54, NLGN1]
GO:0051893;regulation of focal adhesion assembly;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;59.47724087459839;5.769740442447999;0.0019906497260312257;0.6459841598043611;[NRP1, ARHGAP6, PTK2, TEK, EPHA3]
GO:0071480;cellular response to gamma radiation;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;6.444869117505266;0.0020214916980741903;0.6805102716434839;[EGR1, CDKN1A, NOX4]
GO:2000008;regulation of protein localization to cell surface;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;29.0551629072873;6.166155715036245;9.724501545579579E-4;0.6384578026126634;[AKT1, EGF]
GO:0030815;negative regulation of cAMP metabolic process;10.0;0.8259837884571596;0.8282329060895002;9.526741558182179;1399.2283946151745;6.311337724880743;0.04683091514397047;0.7380031166185408;[P2RY13, GABBR1, EDNRB, HTR1E, GPR87, HRH4, GNAI2, CCR2]
GO:0048013;ephrin receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[AP2M1, MMP9, EPHA3, SDC2, LYN, PTK2]
GO:2001214;positive regulation of vasculogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;246.74152534447236;7.474488534686424;0.008258216800323579;0.7331650565203278;[TMEM100, CEACAM1]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[FGF5, GAB1, BTC, CHI3L1, HBEGF, ENG, CD19, TGFB1, TRAT1, EGF, PTK2, CD28, NOX4, TEK]
GO:0035385;Roundabout signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;26.50247477320489;7.8311634786251565;8.87013979980389E-4;0.7236063770733796;[ROBO2]
GO:0035264;multicellular organism growth;3.0;1.0;0.6981203125901445;9.628524252492122;22.582921643529833;5.382624473008031;7.558300640989654E-4;0.47338797845741154;[BRCA2, HHEX, SLITRK6, RMI1]
GO:0035025;positive regulation of Rho protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;339.6245583269611;6.481236761676141;0.01136692832494487;0.7466917612613706;[F2R, GPR18, F2RL3]
GO:1903427;negative regulation of reactive oxygen species biosynthetic process;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;200.2914960164085;6.686031174322154;0.00670357612102564;0.692843310444282;[CAV1, SLC30A10]
GO:0046086;adenosine biosynthetic process;10.0;0.9326813400603323;0.8815816818910864;9.604993755081928;3098.941052133345;9.083926447120524;0.10371876814902463;0.8797934328124444;[NT5E]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, F13A1, LAMP2, CD36, ACTN1, ANXA5, ACTN4, F5, PECAM1, TLN1, STXBP2, FLNA, LYN, TGFB1, EGF, LHFPL2, CD9]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[IL5RA, FGF5, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, LAT, LRRK2, SPTAN1, MAP4K1, DUSP6, HBEGF, EGF, TEK]
GO:0006814;sodium ion transport;7.0;0.811012628672052;0.7564256795932265;9.310070521373587;34.16983994150393;4.629579150867016;0.001143633791982704;0.5876762583299873;[SLC8A1, SCN1A, SLC13A1, SLC6A16, SLC6A15, ATP1B2, ATP1B1, SLC5A7, SGK1, SLC22A4, SLC24A1, SLC24A4, SLC38A11, SLC5A4, SLC38A6, SLC17A6, SCN3A, SLC12A1, SLC4A7, SLC6A6]
GO:0071392;cellular response to estradiol stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;338.1710882258028;6.221725566191056;0.011318281988697268;0.6412996473849828;[ABCB4]
GO:0051781;positive regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.438940185618286;42.28939918509474;5.358233019883872;0.0014153881327367882;0.5642612976810992;[CXCR5, TGFA, FGF5, RACGAP1, NUP62, PDGFC, SVIL, TGFB1, TAS2R13, CDC6, CIT, BTC]
GO:0071277;cellular response to calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;5.433268205826786;0.0026274528238337297;0.6009779013089371;[NLGN1, CPNE5, KCNH1, MEF2C, TUBG1]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[CDKN1A, MYB, PDGFC, TGFB1, CDC6, BTC]
GO:0023041;neuronal signal transduction;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;7.9853141584524145;7.75488093814194E-4;0.6986103492792611;[NLGN1]
GO:2001222;regulation of neuron migration;7.0;0.7866048967936545;0.7442218136540277;9.510741216835738;102.29339340919134;6.221725566191056;0.0034236678193284823;0.6690987000520388;[FLRT2, FLNA]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, PID1, ITGAM, AKT1, CD36, CD177, DNM2, AGTR1, TLR4, FPR2, PTGS2, GNAI2, TGFB1, NOX4, PTX3]
GO:0034163;regulation of toll-like receptor 9 signaling pathway;8.0;0.8653626801206646;0.8076813400603323;9.4949928598676;90.3094294018114;7.8311634786251565;0.0030225753288688696;0.7754860644832351;[FCRL3]
GO:0034166;toll-like receptor 10 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;9.777073627680469;0.013811191226989502;0.9481203125901445;[TLR10]
GO:0033198;response to ATP;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;115.93137747960115;6.375876246018314;0.0038801188727762915;0.6491829203200885;[PTGS2, SLC8A1, P2RX5, P2RX1]
GO:2000392;regulation of lamellipodium morphogenesis;8.0;0.8933024483968273;0.8216512241984136;9.461470167828956;53.99527749392168;7.379178354882098;0.0018071733451267124;0.7523715242355574;[PDPN]
GO:1904646;cellular response to amyloid-beta;7.0;1.0;0.8509193652572005;9.628524252492122;273.93391051768003;6.518977089658987;0.009168321460513012;0.6843001567857983;[LRP1, FPR2, GRM5, CD36, FCGR2B, TLR4]
GO:0002587;negative regulation of antigen processing and presentation of peptide antigen via MHC class II;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;144.69507589410327;9.083926447120524;0.004842813973061743;0.8154717862087246;[HLA-DOA, HLA-DOB]
GO:0002224;toll-like receptor signaling pathway;11.0;0.6763753087927167;0.7706166067260205;9.040737587590003;409.6592600291497;5.311165509025885;0.01371092676377766;0.7040422034557006;[ITGAM, CTSS, CD36, CD180, TLR1, BTK, TLR8, TLR10, TLR7, TLR5, TLR4, S100A8, TLR2, COLEC12, UNC93B1, LY96]
GO:0005977;glycogen metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.523163736834295;182.57737249811964;5.885253329569843;0.006110700348544658;0.6518914942236709;[PPP1R3A, PYGL, AKT1, PPP1CA]
GO:0072112;glomerular visceral epithelial cell differentiation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;72.77032193269073;7.8311634786251565;0.002435557186049328;0.7514054297404357;[BASP1, CD24]
GO:2000145;regulation of cell motility;5.0;0.46812423412493653;0.5243031289233886;6.883086519318291;34.54403569627484;3.0677692874221707;0.001156157787140571;0.44712687588555144;[SPINT2, C3AR1, AKT1, MEF2C, CLDN7, PADI2, FPR2, PLA2G7, FLRT2, PDGFC, ELANE, LYN, JAG1, ACE, JUP, PLK2, NOX4, GPR18, ANXA3, TACR3, TMEFF2, HBEGF, ENG, PTAFR, PTGS2, GPNMB, FLNA, JAM3, PKN1, PLXND1, SLC8A1, CXCL16, PYCARD, DACH1, F2R, ADAM9, CD274, CD151, TACSTD2, CORO1A, LRP1, P2RY6, SEMA4B, LGALS3, IL1R1, ACTN4, BTC, PFN1, CCR1, PTK2, BST1, NRP1, PTPRR, NRP2, PTPRK, CCR6, CCR2, GAB1, CEACAM1, CEACAM6, SGK1, GNAI2, CXCR2, PDPN, IL6R, C5AR1, STAP1, TGFB1, DOCK5, MCTP1, TNFAIP6, LAMC2, CXCL1, CXCL2, ARAP3, MMP9, LAMA3, EGF, TEK]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PYCARD, PPP2R1A, TNFSF12, CAV1, G0S2, INHBA, PPP1CA, MAL, LTBR, ATF3, ITM2C]
GO:0033189;response to vitamin A;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;42.3983228833862;6.781341354126479;0.0014190337108936392;0.6977174774718518;[ARG1, ABCB4]
GO:0035249;synaptic transmission, glutamatergic;8.0;1.0;0.875;9.628524252492122;25.73829654599903;6.444869117505266;8.61437622431563E-4;0.7045909063862833;[P2RX1, SLC17A6]
GO:0003376;sphingosine-1-phosphate signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;50.14720301582843;7.292166977892469;0.001678381755387122;0.6960420709600095;[SPNS1, S1PR3, GPR6]
GO:0006884;cell volume homeostasis;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;49.534292112730455;6.444869117505266;0.0016578681790444336;0.6527112189764278;[SLC12A1]
GO:0006885;regulation of pH;8.0;0.6997970393407541;0.724898519670377;8.992535485772125;35.59382883917596;5.266214121163619;0.0011912934188809815;0.6443144350603088;[LRRK2, EDNRB, SLC11A1, AVPR1A, SLC4A7, SLC26A8, SLC26A7, SLC26A3]
GO:0060326;cell chemotaxis;5.0;0.6393367784920305;0.6099094011069355;8.152617732682543;30.286927728949156;4.458953633836253;0.0010136762146226118;0.5182721080578558;[CSF3R, CXCL16, LGALS3, EDNRB, CCRL2, C3AR1, IL6R, CXADR, AGTR1, S100A8, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, CCR10, CCR1, EGR3, AZU1, DEFA1, NR4A1, NRP1, HMGB2, CXCL1, CXCL2, CCR9, FFAR2, CCR6, CCR2, RHOG, GAB1, HBEGF, CXCR5, CXCR4, CXCR1, CXCR2]
GO:0006879;cellular iron ion homeostasis;10.0;0.8436909121759173;0.837086467948879;9.474373572664863;186.73793370626092;5.69953618377475;0.006249950587919157;0.706715557354699;[TFRC, SLC40A1, HEPH, SLC11A1, CYBRD1, LCN2, LTF]
GO:0032922;circadian regulation of gene expression;6.0;1.0;0.8231203125901445;9.628524252492122;31.18462308171688;5.769740442447999;0.0010437212702063816;0.618185107137305;[PPP1CA, MC3R, LGR4]
GO:0071333;cellular response to glucose stimulus;8.0;1.0;0.875;9.628524252492122;272.3004295980195;5.69953618377475;0.009113650324169357;0.6664745454937787;[NOX4]
GO:0030509;BMP signaling pathway;11.0;0.7090535922965819;0.7869557484779532;9.133828010656014;282.55034729266697;5.202362649177086;0.009456705845082177;0.6984780201431826;[TMEM100, EGR1, TGFB1, RUNX2, ENG]
GO:0072540;T-helper 17 cell lineage commitment;8.0;1.0;0.875;9.628524252492122;46.25983793501841;7.9853141584524145;0.0015482751445338478;0.7833693374183408;[LY9]
GO:0071577;zinc ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.35659053700848;134.4975615453565;6.599019797332524;0.00450151234497627;0.7337148045016781;[SLC30A10]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[SLC8A1, AKT1, KCND2, PTGS2]
GO:0051968;positive regulation of synaptic transmission, glutamatergic;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;135.83014596643335;6.375876246018314;0.004546112746301595;0.701062607729944;[NLGN1, TNR, PTGS2, KMO]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, GRM5, EDNRB, CCRL2, CCR9, CCR6, CCR2, AVPR1A, ATP1B1, LAT2, BTK, AGTR1, CXCR5, CXCR4, FPR2, CXCR1, CXCR2, CCR10, CCR1, AZU1, SELE, LAT]
GO:0051965;positive regulation of synapse assembly;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;224.643362448917;5.602686357784832;0.007518611175264769;0.6374410061458773;[NLGN1, AMIGO3, FLRT2, SLITRK6]
GO:0071219;cellular response to molecule of bacterial origin;5.0;0.7980440201809971;0.6892630219514189;9.253830803050711;59.34640842185874;4.720827822332161;0.001986270881579593;0.5316643662359317;[PYCARD, EDNRB, GHSR, MEF2C, CD180, ADAM9, CD274, STAP1, NLRP3, ABCA1, FZD5, DEFA4, DEFA1, HMGB2, CXCL1, TREM2, CXCL2, CTSG, CD36, ARG1, PDCD1LG2, TNFRSF1B, TLR1, TLR4, TLR2, CEBPE, NR1H2, LILRB1, LILRB2, FCGR2B]
GO:0051966;regulation of synaptic transmission, glutamatergic;7.0;0.811012628672052;0.7564256795932265;9.405380701177911;30.61939422688933;5.528578385631111;0.001024803569108247;0.6336511210035629;[MEF2C, NLGN1, LRRK2, PTGS2, KMO, GRM5, CNR1, TNR]
GO:0071217;cellular response to external biotic stimulus;4.0;1.0;0.75;9.628524252492122;54.03966511499906;9.777073627680469;0.001808658958857907;0.75;[ABCB4]
GO:0051964;negative regulation of synapse assembly;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;219.30269939314178;7.9853141584524145;0.007339863989072673;0.7592887026755414;[ROBO2, PTK2, TLR2]
GO:2000171;negative regulation of dendrite development;10.0;0.8653626801206646;0.8479223519212526;9.59462270081644;583.3629276187952;6.481236761676141;0.01952463219485162;0.7466917612613706;[NLGN1, DCC, PLK2]
GO:0006651;diacylglycerol biosynthetic process;8.0;1.0;0.875;9.628524252492122;411.67721384051237;8.390779266560578;0.013778465861803443;0.8041048419030481;[MOGAT2]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[TFRC, SLC11A1, FPR2, IGHA1, ELANE, MSR1, MARCO, DENND1B, ASGR1, ASGR2, CD36, ANXA3, CEACAM1, RHOU, CD302, IGKC, CXCR1, CXCR2, SORT1, LILRB1, SIGLEC1, RAMP1, SCARB2, NCF4, HP, CXCL16, PYCARD, AP2M1, CD93, TSC2, PRTN3, CALCRL, PLD4, CORO1A, IGLV1-44, CD163, SYT2, CAV1, LRP1B, MARCH3, IGKV3-20, LRP12, LRRK2, GHR, DNM2, PECAM1, COLEC12, NLGN1, LRP1, CEBPE, FCGR1B, NLGN4Y, CD9, FCGR2B]
GO:1901557;response to fenofibrate;5.0;1.0;0.7902410118609202;9.628524252492122;104.6800071720804;9.777073627680469;0.00350354563415944;0.7902410118609202;[ABCB4]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[SCARB2, TFRC, HP, CXCL16, AP2M1, CALCRL, FPR2, IGLV1-44, IGHA1, MSR1, CD163, CAV1, LRP1B, MARCO, IGKV3-20, LRP12, ASGR1, ASGR2, CD36, DNM2, CEACAM1, COLEC12, LRP1, IGKC, CXCR1, CXCR2, FCGR1B, LILRB1, CD9, FCGR2B, RAMP1]
GO:0006656;phosphatidylcholine biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.398000593880289;749.286726231254;6.343086423195323;0.025077952412686653;0.6993857346658935;[SLC44A5, SLC44A1]
GO:0007621;negative regulation of female receptivity;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;31.667433361888115;8.390779266560578;0.0010598804957826708;0.7800242071602487;[AVPR1A]
GO:0032913;negative regulation of transforming growth factor beta3 production;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;85.63944001314535;9.777073627680469;0.002866274986747803;0.8509193652572005;[CD24]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[MEF2C, TGFB1, ARG1, CAV1, NOX4]
GO:0009914;hormone transport;4.0;0.5756379274792419;0.5378189637396209;7.480089839325334;21.707737847050485;5.358233019883872;7.265384500450821E-4;0.524020285820179;[ABCB4, LYN, GHSR, INHBA, BTK]
GO:0051970;negative regulation of transmission of nerve impulse;7.0;0.9326813400603323;0.8172600352873667;9.567899630675686;162.3929256644701;8.16763571524637;0.005435145077845198;0.7686126355688037;[AVPR1A]
GO:0051971;positive regulation of transmission of nerve impulse;7.0;0.9326813400603323;0.8172600352873667;9.567899630675686;161.98963704071667;7.9853141584524145;0.005421647370544368;0.7592887026755414;[CHRNB4, TNR]
GO:0070474;positive regulation of uterine smooth muscle contraction;9.0;1.0;0.896240625180289;9.628524252492122;87.9006140514566;7.697632086000634;0.0029419544468855647;0.7898978880348613;[TACR3]
GO:0098942;retrograde trans-synaptic signaling by trans-synaptic protein complex;7.0;1.0;0.8509193652572005;9.628524252492122;46.63437644952677;9.777073627680469;0.0015608106115516636;0.8509193652572005;[NLGN1]
GO:0098700;neurotransmitter loading into synaptic vesicle;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;24.67221757710373;7.697632086000634;8.257569187514192E-4;0.6838982747154925;[SLC17A6]
GO:0071320;cellular response to cAMP;7.0;1.0;0.8509193652572005;9.628524252492122;327.37290077043656;5.825829909099042;0.01095687637230394;0.6488525777373224;[PTAFR, AQP9, SLC8A1, KCNQ1, NOX4, SLC26A3]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[SIRPB1, PYCARD, STAP1, CD36, SLC11A1, AZU1, DNM2, PTX3, FCGR2B]
GO:0050765;negative regulation of phagocytosis;8.0;0.8436909121759173;0.7968454560879586;9.503361109538115;175.4194889364855;7.069023426578259;0.005871132427413739;0.7365101867784198;[TGFB1, PRTN3, FCGR2B, TLR2]
GO:0019934;cGMP-mediated signaling;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;28.507808342730176;7.069023426578259;9.541306898693577E-4;0.7365101867784198;[EDNRB, PRKAR2B, CD36]
GO:2000060;positive regulation of ubiquitin-dependent protein catabolic process;10.0;0.811012628672052;0.8207473261969463;9.483342242647623;1661.590298646008;5.192106149009898;0.055611931961498426;0.6807655617789147;[LRRK2, AKT1, EGF, PLK2, CAV1, PTK2, CCDC22]
GO:0014002;astrocyte development;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;34.09911675737102;6.832634648514029;0.001141266750656509;0.639662265535933;[PLP1, TSPAN2, S100A8]
GO:1903861;positive regulation of dendrite extension;10.0;1.0;0.9152410118609203;9.628524252492122;830.9775978573329;6.832634648514029;0.027812072369000178;0.7646622655359331;[SYT2, CPNE5]
GO:1905802;regulation of cellular response to manganese ion;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;23.691248258258653;9.777073627680469;7.929247584647443E-4;0.75;[SLC30A10]
GO:1902533;positive regulation of intracellular signal transduction;7.0;0.5547065974044363;0.6282726639594187;7.95454781892045;189.47637744599322;2.856402123431786;0.006341603835448636;0.4969959026857851;[, AKT1, PROK2, ATF3, SEH1L, FPR1, FPR2, SLC30A10, IQGAP3, PDGFC, ELANE, LYN, NDFIP2, FZD5, PLK2, NOX4, GPR18, EZH2, GPR37, FCRL3, DUSP6, HBEGF, ENG, GPNMB, FLNA, PKN1, CTGF, FGF5, PYCARD, MAP2K2, F2R, ADAM9, S100A8, TNFRSF11A, NACC2, DRD4, TNFRSF10B, CSPG4, CCDC22, LRRK2, TREM2, NLGN1, P2RX5, FCGR2B, ACTN4, BTC, EPHA3, TGFA, CD19, CCR1, PTK2, MARCO, CD28, CD24, NRP1, IFNA2, PRL, CD3E, CD36, MAP4K1, GAB1, BANK1, TLR7, TLR4, TLR2, CXCR4, GNAI2, NLRP12, F2RL3, IL6R, C5AR1, RASGRP4, TGFB1, CAV1, GH1, GHR, NUP62, CHI3L1, LTF, TRAT1, EGF, CD4, LTBR, TEK]
GO:0006855;drug transmembrane transport;5.0;0.5781283279524737;0.5793051758371571;7.293149336675085;29.084245973375534;5.407625775213448;9.73423538606871E-4;0.5667872454856517;[ABCB4, SLC1A3, SLC7A11, SLC17A6, SLC19A2, ABCC3, ABCA8]
GO:0050892;intestinal absorption;4.0;0.811012628672052;0.655506314336026;9.176539128749065;23.07461412231494;6.375876246018314;7.722865688694012E-4;0.576062607729944;[MOGAT2, ABCB4, KCNQ1, CD36]
GO:0002018;renin-angiotensin regulation of aldosterone production;12.0;1.0;0.9481203125901445;9.628524252492122;135.1247056788498;8.390779266560578;0.0045225022947312146;0.8772251544931927;[AGTR1]
GO:0050772;positive regulation of axonogenesis;10.0;0.7436939687323844;0.7870879962271125;9.36383169826504;884.0118179988558;5.395046993006588;0.02958707998943757;0.6911439659786198;[ROBO2, CYFIP1, NRP1, PLXND1]
GO:0071475;cellular hyperosmotic salinity response;7.0;0.9326813400603323;0.8172600352873667;9.567899630675686;243.83975882422638;8.390779266560578;0.008161097286311265;0.7800242071602487;[ABCB4]
GO:0140058;neuron projection arborization;8.0;0.8436909121759173;0.7968454560879586;9.420884887713877;64.60914726719044;7.57984905034425;0.0021624100145753813;0.7626338329336335;[NRP1, NLGN1, LRRK2]
GO:0071236;cellular response to antibiotic;4.0;0.6369964171292115;0.5684982085646058;7.703233390639544;41.40086873190647;5.085725745451326;0.0013856498180940687;0.5100842511328143;[IL18RAP, MYB, MEF2C, ARG1, PCNA, ABCB4, GNAI1, FOXO1, EGR1, EZH2]
GO:0016311;dephosphorylation;5.0;0.6835726970475526;0.6320273603846966;8.32924126836186;24.405590426795786;4.076630054289783;8.168331479794688E-4;0.4987200624199847;[PPP2R1A, PFKFB4, PTPRE, ALPL, PTPRR, PTPRK, IMPA2, DUSP2, DUSP1, DUSP6, ACPP, FBP1, TPTE, NT5E, PPP1CA]
GO:2001025;positive regulation of response to drug;5.0;0.6519675769143192;0.6162248003180799;7.963516488903211;42.538124801348104;6.481236761676141;0.0014237127552742665;0.6216917612613706;[ABCB4, PAWR, RETN, DRD4]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, CYFIP1, TFRC, SLA2, MYB, C3AR1, UBASH3A, MEF2C, CXADR, HHLA2, FPR1, FPR3, FPR2, IGHA1, HLA-DQA1, ELANE, LYN, HLA-DRB4, FZD5, DENND1B, SIGLEC9, HLA-DPA1, ARG1, FCRL3, NFAM1, PAWR, PAX5, MMP12, FCER2, TLR10, HLA-DQB1, PTAFR, UNG, NR1H2, HLA-DPB1, PKN1, CLC, LGR4, PYCARD, IGHG1, FCGRT, GRAP2, IL13RA2, CD177, LAG3, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, CD274, LY96, IGLV1-44, BMX, BCL6, HLA-DRA, LAT, ITGAM, TREM2, TREM1, FCGR3A, CR2, CR1, UNC93B1, NLRC4, FCGR1B, FCGR2A, FCGR2B, ICAM2, LGALS3, ICOSLG, SLC11A1, BTK, STXBP2, CD1E, CD1B, CD1A, CD79B, CD79A, CD19, SH2D1A, PTK2, MARCO, CD28, CD24, CD200, IGHM, IFNA2, CD3G, CD3E, CTSS, FCER1A, FFAR2, CTSG, MUC15, CD36, CD33, CCR2, LAT2, TLR1, CEACAM1, IGHD, TLR8, TLR7, TLR5, TLR4, TLR2, IGKC, LILRB1, LILRB2, MLH1, IL18RAP, IL6R, OSCAR, CD300C, C5AR1, STAP1, NLRP3, TGFB1, CAV1, IGKV3-20, HMGB2, LTF, COLEC12, CLEC12B, SAMHD1, CNR1, TRAT1, CD4]
GO:0035176;social behavior;3.0;1.0;0.6981203125901445;9.628524252492122;22.58175877758554;5.8067817141283475;7.557911440223213E-4;0.49507939949363344;[NLGN4Y, NRXN3, AVPR1A, DRD4]
GO:0036146;cellular response to mycotoxin;5.0;0.8933024483968273;0.736892236059334;9.427853557029971;58.05627655683236;8.16763571524637;0.001943091329100457;0.7079342821725234;[EGR1, ABCB4]
GO:0060333;interferon-gamma-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.514393750639154;0.00101047745553359;0.6329257181104212;[CIITA, HLA-DPA1, HLA-DQB1, PTAFR, FCGR1B, HLA-DQA1, HLA-DRB4, HLA-DPB1, HLA-DRA]
GO:1900244;positive regulation of synaptic vesicle endocytosis;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;265.8961164942356;7.9853141584524145;0.008899303728093307;0.7833693374183408;[NLGN1, LRRK2]
GO:0048469;cell maturation;3.0;0.6954798709641801;0.5458602480722345;8.242229891372231;25.22197897315013;4.886724499458715;8.441569379239579E-4;0.4480276307483924;[CDKN1A, BRCA2, ROPN1L, FBXO5, RUNX2, BTK, FZD5, NR4A2, SLC26A8, PLP1, SLC26A3]
GO:0048468;cell development;3.0;0.5052934683962566;0.45076704678827284;6.510574346213882;28.41553699003407;3.2909128387363804;9.510424507334451E-4;0.36641774820622075;[AKT1, MEF2C, CXADR, RUNX2, ABCB4, GJC1, SFN, TSPAN2, LYN, JAG1, BCL11B, SDC1, ROBO2, GABRB1, ENG, TLR2, FLNA, JAM3, GSN, GABRA5, MLH1, SULF2, PLP1, ARID4A, SLC8A1, CLEC5A, MSH2, S100A8, TGFB1, INHBA, BCL6, LSR, SLC4A7, KLF5, CD9]
GO:0002034;regulation of blood vessel diameter by renin-angiotensin;8.0;1.0;0.875;9.628524252492122;80.79521007181147;8.67846133901236;0.002704142970135261;0.8188169164668168;[AGTR1]
GO:1900127;positive regulation of hyaluronan biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;589.7686013946351;8.390779266560578;0.019739024331396862;0.8253454670833372;[EGF]
GO:1901216;positive regulation of neuron death;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;58.38287487682085;5.370354380416217;0.001954022280951067;0.5977604853516485;[ITGAM, MYB, KMO, TLR4, EGR1, FCGR2B, UBE2M]
GO:0006631;fatty acid metabolic process;7.0;0.5408746917014966;0.6213567111079488;7.849668188099975;91.0232021896581;4.037280715501235;0.0030464646617242943;0.5573860888006872;[, SCARB2, ACSL1, POR, SLC27A2, MGST1, PRKAR2B, CYP4F2, CYP4F3, TBXAS1, TECR, GHR, ELOVL4, PTGS2, ALOX5, SCD, PLP1]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, ATP1B1, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, ELANE, CCR10, DRD4, CCR1, TGFB1, WFS1, CAV1, CD24, GPR18, ATP2A3, GRM5, CCR9, CCR6, CD36, CCR2, TRPC7, CD52, PTGIR, TRPC1, AVPR1A, SLC24A1, SLC24A4, CXCR5, CXCR4, CXCR1, SV2A, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, GRINA, F2RL3]
GO:0070371;ERK1 and ERK2 cascade;10.0;1.0;0.9152410118609203;9.628524252492122;233.3964595037646;6.481236761676141;0.007811569456414605;0.7466917612613706;[MAP2K2, EGF, IQGAP3]
GO:0002027;regulation of heart rate;7.0;0.7043150770688792;0.7030769037916401;8.712233520617966;26.867502833526505;5.233778845410465;8.992311406554274E-4;0.6185750588070984;[KCNE3, SLC8A1, JUP, CAV1, TACR3, AVPR1A, MC3R, KCNQ1]
GO:0090091;positive regulation of extracellular matrix disassembly;7.0;1.0;0.8509193652572005;9.628524252492122;86.12905664991239;7.8311634786251565;0.0028826620149540304;0.7514054297404357;[PDPN]
GO:0070493;thrombin-activated receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;7.57984905034425;9.028936615729279E-4;0.710754145523778;[F2R, F2RL3]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[HMGB2, CXCL1, CXCL2, PYCARD, EDNRB, CTSG, CD36, GHSR, MEF2C, ARG1, CD180, PDCD1LG2, TNFRSF1B, ADAM9, TLR4, CD274, CEBPE, STAP1, NLRP3, ABCA1, NR1H2, DEFA4, LILRB1, DEFA1, LILRB2]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, SLPI, BTK, LY9, IGHA1, LYN, SH2D1A, PTK2, MARCO, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, LILRA5, IGKC, LGR4, PYCARD, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, LCN2, ITGAM, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, PTX3]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[PTPRR, LYN, DUSP1, DUSP6, NLRP12, TLR4, ATF3]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[, ELANE, BARD1, ST14, ACE, AZU1, OLR1, MMP12, FAM105A, ADAM28, APEH, IGHG1, RUVBL1, ADAM2, ADAM9, ADAM7, IGLV1-44, CLCA4, WFS1, DHCR24, ADAMTS20, HM13, RNF24, ANPEP, SKP2, CTSS, CTSG, MME, IGKC, RANBP1, ADAM12, PRTN3, PSEN2, TRHDE, NLRP3, TGFB1, IGKV3-20, MMP8, MMP9, LTF]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, PYCARD, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, SLC30A10, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, CHI3L1, GNAI2, GPNMB, CD4, TEK]
GO:0045088;regulation of innate immune response;6.0;0.4673148936341128;0.556777759407201;6.780712109014753;42.469229973879315;3.8881956693475885;0.0014214069074002054;0.52196281994017;[ICAM2, BTK, LYN, SH2D1A, MARCO, CTSS, FFAR2, MUC15, CD36, ARG1, FCRL3, MMP12, TLR1, CEACAM1, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, NR1H2, LILRB1, LGR4, PYCARD, IL18RAP, LAG3, CD180, CLEC4D, S100A8, LY96, CAV1, ITGAM, HMGB2, CR1, LTF, COLEC12, UNC93B1, CLEC12B, NLRC4, SAMHD1, FCGR2B]
GO:0072679;thymocyte migration;8.0;0.8933024483968273;0.8216512241984136;9.533214072687796;31.84507234699532;9.083926447120524;0.0010658259127495017;0.839552420951524;[CCR6]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[HLA-DPA1, KIF16B, TLR4, TLR2, STXBP2, CD58, GSN, ZYX]
GO:0050667;homocysteine metabolic process;8.0;0.8436909121759173;0.7968454560879586;9.456673995565463;188.66608657723927;7.292166977892469;0.006314484129285878;0.747921758369865;[NOX4]
GO:0045806;negative regulation of endocytosis;7.0;0.7192862368539868;0.710562483684194;9.057979394024509;124.57926064357885;5.8650506222523235;0.004169555739685066;0.6508583268319309;[MCTP1, LGALS3, TGFB1, NR1H2, CAV1, LILRB1, PRTN3, FCGR2B, EPHA3, TLR2]
GO:0042416;dopamine biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.590783924509275;507.8534772351106;7.474488534686424;0.01699739884460309;0.7572456912631272;[NR4A2, GPR37]
GO:0042538;hyperosmotic salinity response;5.0;0.8933024483968273;0.736892236059334;9.4949928598676;42.97243876554825;7.474488534686424;0.0014382488527988541;0.6724867031240476;[ABCB4, TACR3]
GO:0060084;synaptic transmission involved in micturition;9.0;1.0;0.896240625180289;9.628524252492122;25.73829654599903;8.67846133901236;8.61437622431563E-4;0.8400575416471059;[CHRNB4]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[, NUP107, TFRC, AKT1, LYN, ABCA1, MMP12, CSE1L, AP2M1, ACAP1, SLC27A2, LIN7A, ITGB6, LRP1, ACTN4, MSR1, EGR2, POLA2, CD24, CD3G, CD36, STX11, RAMP1, SCARB2, NUP155, NASP, NUP62, NUP133, TBC1D9, CHI3L1, NUP54, NUP35, RAN, NUP85, NUP88, DENND1B, LAMP2, RAB32, CALCRL, BCL6, CCDC22, NLGN1, UNC93B1, NLRC4, STXBP2, TRAM2, XPO1, TMED6, TLR4, TLR2, RANBP1, LILRB1, NUPL2, TSC2, ATP1B1, HGS, SUCNR1, NLRP3, TGFB1, LRP1B, DNM2]
GO:0051491;positive regulation of filopodium assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;6.409777797693995;0.006704083591926775;0.7240369598395108;[NRP1, NLGN1]
GO:0021954;central nervous system neuron development;5.0;0.7980440201809971;0.6892630219514189;9.0094850440859;34.232648149996464;6.343086423195323;0.0011457359261972313;0.6146267465268138;[ROBO2, GABRB1]
GO:0042531;positive regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1230.2749798860389;5.618190544320798;0.04117619640118775;0.7197434780388068;[IFNA2, GHR, IL6R, LYN, GH1]
GO:0002087;regulation of respiratory gaseous exchange by neurological system process;6.0;1.0;0.8231203125901445;9.628524252492122;40.361908422019745;7.212124270218933;0.0013508767515257331;0.6919486831672181;[NLGN1]
GO:0007413;axonal fasciculation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;31.514364772604104;6.7325511899570465;0.0010547574278521217;0.6952223462072524;[NRP1, CNR1, NCAM2, EPHA3]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[CYFIP1, NRP1, CPNE5, CXCL16, AKT1, AVPR1A, S100A8, HBEGF, SFN, SYT2]
GO:0031999;negative regulation of fatty acid beta-oxidation;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;724.8195482541148;8.16763571524637;0.024259057984822387;0.8139338954918922;[CNR1, AKT1]
GO:0052695;cellular glucuronidation;9.0;0.8653626801206646;0.8289219652406215;9.446202695698167;85.04062765322598;6.8867018697843045;0.0028462332759574376;0.7484268790654467;[UGT2A3]
GO:0051001;negative regulation of nitric-oxide synthase activity;7.0;1.0;0.8509193652572005;9.628524252492122;123.18001952109483;7.8311634786251565;0.0041227243985507795;0.7514054297404357;[CNR1, CAV1]
GO:0051482;positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;292.0931097099921;6.139487467954083;0.009776093515261451;0.7620939872166814;[F2R, C3AR1, AGTR1, GPR18, GPR157, F2RL3]
GO:0007409;axonogenesis;8.0;0.6873818243518346;0.7186909121759173;8.667113085337498;64.60914726719044;4.956792062075433;0.0021624100145753813;0.6284905765689417;[NRP1, STMN1, DCC, SLITRK6, LINGO1, GP5, PTK2, NR4A2, LRFN4, OGN]
GO:0032849;positive regulation of cellular pH reduction;12.0;0.9326813400603323;0.9144609826203107;9.585964638073326;185.54450294029945;8.390779266560578;0.0062100075342003845;0.8772251544931927;[AVPR1A]
GO:0032729;positive regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.6339389012889365;0.002183412136085803;0.6112402100070131;[CD3E, PYCARD, IL6R, CCR2, HLA-DPA1, SLC11A1, TLR8, TLR7, TLR4, FZD5, CD2, HLA-DPB1]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[CTSS, HLA-DOA, HLA-DOB, AP2M1, HLA-DPA1, LAG3, DNM2, HLA-DQB1, HLA-DMA, RACGAP1, HLA-DQA1, HLA-DRB4, HLA-DPB1, HLA-DRA, FCGR2B]
GO:0032962;positive regulation of inositol trisphosphate biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;985.0638483814348;8.16763571524637;0.03296920050541953;0.8139338954918922;[LHCGR]
GO:0032600;chemokine receptor transport out of membrane raft;11.0;1.0;0.9324289523296623;9.628524252492122;247.9928586842006;9.777073627680469;0.008300097801077391;0.9324289523296623;[CD24]
GO:0042309;homoiothermy;6.0;1.0;0.8231203125901445;9.628524252492122;21.014590666490108;9.083926447120524;7.033394377036888E-4;0.7876727335416686;[MC3R]
GO:0002092;positive regulation of receptor internalization;9.0;0.9326813400603323;0.8625812952104552;9.585964638073326;393.55365953464764;6.599019797332524;0.013171886809326083;0.7337148045016781;[EGF, SELE]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[CYFIP1, SPINT2, CDH5, CDH3, CDH1, MEF2C, ACTN1, CLDN3, SLC1A3, ST14, BCL11B, BCL6, NOX4, NRP1, PDPN, SLITRK6, FLNA, TEK]
GO:0002093;auditory receptor cell morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;63.917378446602264;9.083926447120524;0.0021392571347018143;0.8154717862087246;[SLITRK6]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, KCNG2, TCL1A, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CAV1, CD3G, CD3E, KCND2, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, NLRC4, SAMHD1, RAD51, P2RX1]
GO:0021940;positive regulation of cerebellar granule cell precursor proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;202.6652060662171;9.083926447120524;0.006783022060192384;0.8154717862087246;[EGF]
GO:0006573;valine metabolic process;8.0;0.811012628672052;0.780506314336026;9.392135474427892;166.53491036647193;7.57984905034425;0.00557377357827698;0.7626338329336335;[GHR]
GO:0009967;positive regulation of signal transduction;6.0;0.44130843764162375;0.5437745314109563;6.712834686611667;140.23187634019237;2.4492930892588385;0.004693434700611163;0.44837727507861835;[, SLA2, AKT1, ATF3, FPR1, FPR2, SLC30A10, IQGAP3, PDGFC, SFN, LYN, JAG1, JUP, NOX4, GPR18, EZH2, ARHGAP6, GPR37, DUSP6, MMP12, FLNA, BIK, LRG1, PKN1, LGR4, CTGF, RUVBL1, MAL, S100A8, LY96, TNFRSF11A, TNFRSF10B, LRRK2, HHEX, ADAMTS20, ACPP, SH2B1, FCGR2B, ACTN4, BTC, EPHA3, TGFA, CD19, TSPAN5, CCR1, TNFSF12, PTK2, CD28, CD24, NRP1, CD3E, CD36, GAB1, BANK1, GNAI2, PPP1CA, NLRP12, IL6R, RASGRP4, CAV1, INHBA, GH1, GHR, NUP62, MMP9, CHI3L1, EGF, CD4, TEK, CYFIP1, PROK2, SEH1L, ELANE, NDFIP2, FZD5, PLK2, FCRL2, FCRL3, NFAM1, HBEGF, ENG, GPNMB, GSN, G0S2, SULF2, FGF5, PYCARD, CDH3, GRAP2, MAP2K2, CD180, F2R, ADAM9, NACC2, DRD4, CSPG4, CCDC22, LAT, TREM2, NLGN1, P2RX5, PPP2R1A, SKP2, IL1R1, POR, SH2D1A, MARCO, ITM2C, IFNA2, PRL, MAP4K1, TLR1, TLR7, TLR5, TLR4, TLR2, CXCR4, F2RL3, GHSR, C5AR1, STAP1, TGFB1, BLNK, LTF, TRAT1, LTBR]
GO:0031989;bombesin receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;9.083926447120524;9.028936615729279E-4;0.7876727335416686;[NMBR]
GO:0007416;synapse assembly;4.0;0.8436909121759173;0.6718454560879586;9.117698628726131;35.85243951974866;5.500407508664414;0.0011999488856252476;0.5312910957882058;[NLGN1, FZD5, PLXND1, PCDHB15, PCDHB14, PCDHB10, CDH1, PCDHB16, SLITRK6, PCDHB4, PCDHB8]
GO:0006448;regulation of translational elongation;8.0;0.7090535922965819;0.729526796148291;9.205667401672088;215.8173094633638;6.8867018697843045;0.007223211124770292;0.7271862538851576;[GRM5]
GO:0051497;negative regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;338.83785420150645;6.781341354126479;0.01134059804585365;0.7792270645443136;[TMEFF2, STMN1, TACSTD2, PFN1, ARHGAP6]
GO:0032956;regulation of actin cytoskeleton organization;7.0;0.559792591703537;0.630815661108969;7.718981747607684;34.11626247365944;3.9689311377000256;0.0011418406023505395;0.553890688213353;[CYFIP1, CELSR1, CTGF, PYCARD, STMN1, MEF2C, PFN1, EPHA3, TACSTD2, CORO1A, STAP1, TGFB1, BST1, NOX4, NRP1, ARHGEF10L, ARHGAP6, SPTAN1, RHOG, CIT, TMEFF2, RHOU, LRP1, EPS8L1, FLNA, JAM3, GSN, TEK]
GO:0099553;trans-synaptic signaling by endocannabinoid, modulating synaptic transmission;9.0;1.0;0.896240625180289;9.628524252492122;101.34340859682928;8.67846133901236;0.0033918726825895485;0.8400575416471059;[GRM5, CNR1, F2R]
GO:0030539;male genitalia development;5.0;1.0;0.7902410118609202;9.628524252492122;66.31594138202881;6.832634648514029;0.002219534877584045;0.639662265535933;[LHCGR, DHCR24, LGR4]
GO:0051496;positive regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;365.07497849775285;5.926926025970411;0.012218730984170163;0.735532224928036;[NRP1, ARHGEF10L, CTGF, NOX4]
GO:0030890;positive regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.1565706318756;6.063501560976162;0.016940604907709607;0.706328376990269;[CDKN1A, TFRC, MEF2C, FCRL3, MSH6, BST1, BCL6]
GO:0031622;positive regulation of fever generation;9.0;0.8436909121759173;0.8180860812682478;9.454170865347344;276.00155245721845;7.8311634786251565;0.009237523575472428;0.7967266896635242;[CNR1, TNFRSF11A, PTGS2]
GO:0031620;regulation of fever generation;8.0;0.7671156992804218;0.7585578496402109;9.168991923113682;57.99935624912111;7.697632086000634;0.0019411862576263126;0.7686572628545723;[EDNRB, CNR1, TNFRSF11A, PTGS2]
GO:1903142;positive regulation of establishment of endothelial barrier;9.0;1.0;0.896240625180289;9.628524252492122;507.13258908748406;8.16763571524637;0.016973271367059242;0.8139338954918922;[CDH5]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[, PROK2, MAP2K2, F2R, ADAM9, C5AR1, FPR1, TGFA, TNFRSF11A, IQGAP3, PDGFC, ELANE, DRD4, TGFB1, FZD5, GH1, NOX4, CSPG4, CD24, EZH2, LRRK2, GHR, MAP4K1, DUSP6, TLR4, CXCR4, EGF, PKN1]
GO:0043647;inositol phosphate metabolic process;6.0;0.7436939687323844;0.6949672969563367;9.280217558223907;87.6170970844922;5.769740442447999;0.002932465389149971;0.618185107137305;[PTAFR, PLD4, IMPA2]
GO:0042438;melanin biosynthetic process;6.0;0.8933024483968273;0.7697715367885581;9.537552474286395;304.50060054653846;7.292166977892469;0.010191361067543862;0.6960420709600095;[TRPC1]
GO:0040014;regulation of multicellular organism growth;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;36.77819272999274;5.557565922504363;0.0012309330124483187;0.5744551915910391;[PRL, GHR, GHSR, NPY1R, GH1]
GO:0043408;regulation of MAPK cascade;9.0;0.6039883530135606;0.6982348016870694;8.647694999480395;157.04088149872794;3.1840290935380327;0.005256016976144841;0.5590720210963193;[, AKT1, PROK2, ATF3, FPR1, FPR2, SLC30A10, IQGAP3, PDGFC, ELANE, LYN, FZD5, NOX4, EZH2, DUSP2, GPR37, DUSP1, FCRL3, DUSP6, GPNMB, PKN1, CTGF, PYCARD, MAP2K2, F2R, ADAM9, TNFRSF11A, FOXO1, DRD4, CSPG4, LRRK2, TREM2, FCGR2B, PPP2R1A, EPHA3, TGFA, CCR1, MARCO, CD24, NRP1, PTPRR, CD36, MAP4K1, CEACAM1, BANK1, TLR4, CXCR4, GNAI2, NLRP12, HGS, C5AR1, HRH4, TGFB1, CAV1, INHBA, GH1, GHR, NUP62, CHI3L1, EGF, CD4, LTBR, TEK]
GO:1904478;regulation of intestinal absorption;6.0;0.7671156992804218;0.7066781622303554;9.223059144383958;30.838810196503868;7.57984905034425;0.0010321472241496931;0.710754145523778;[ABCB4]
GO:0014043;negative regulation of neuron maturation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;593.7949329038761;9.083926447120524;0.019873782023548055;0.8607930461318132;[EDNRB]
GO:0042311;vasodilation;8.0;0.7866048967936545;0.7683024483968273;9.148951172230236;40.37281764308888;6.599019797332524;0.0013512418733372556;0.712474179321389;[EDNRB]
GO:0022900;electron transport chain;4.0;0.7140352122741334;0.6070176061370667;8.475844742553736;29.758801740447502;4.623782033182691;9.96000313069993E-4;0.48646042820481683;[POR, NOX4]
GO:0040018;positive regulation of multicellular organism growth;6.0;1.0;0.8231203125901445;9.628524252492122;145.45792876686207;6.280566066213989;0.004868345972189967;0.6443087532925187;[GHSR, GHR, GH1]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[NRP1, CHL1, MEF2C, F2R, MSH2, LRP1, C5AR1, SLC30A10, CORO1A, WFS1, GABRA5, NR4A2]
GO:0007628;adult walking behavior;4.0;1.0;0.75;9.628524252492122;34.938319875750295;6.518977089658987;0.0011693541237948906;0.5833807915285978;[ABHD12, SCN1A]
GO:0051146;striated muscle cell differentiation;5.0;0.7436939687323844;0.6620879962271125;8.781226392104918;21.75937296335754;5.825829909099042;7.282666309192915E-4;0.5881742243410422;[POPDC3, AKT1, MEF2C, SORT1, AVPR1A, NOX4, SIK1]
GO:0030889;negative regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.3396801226706;7.004484905440688;0.016946733417578675;0.7544503089863854;[LYN, TNFRSF13B, PAWR, BTK, PKN1, FCGR2B]
GO:0097104;postsynaptic membrane assembly;5.0;1.0;0.7902410118609202;9.628524252492122;57.45028169597201;7.57984905034425;0.001922809226467428;0.6778748447945537;[NLGN4Y, NLGN1]
GO:0097105;presynaptic membrane assembly;5.0;1.0;0.7902410118609202;9.628524252492122;57.45028169597201;7.474488534686424;0.001922809226467428;0.6724867031240476;[NLGN4Y, NLGN1]
GO:0038128;ERBB2 signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.36615998802463;32.38857880465376;6.343086423195323;0.0010840165847632744;0.7206263598461826;[PTPRR, EGF, GAB1, BTC, HBEGF]
GO:0038007;netrin-activated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;7.697632086000634;8.87013979980389E-4;0.7167775754447168;[DCC, PTK2]
GO:0046928;regulation of neurotransmitter secretion;7.0;0.6493065804076676;0.6755726554610344;8.817594036275793;103.1091377978561;5.71663061713405;0.0034509700498948056;0.6432681208679463;[NLGN1, MCTP1, LRRK2, MEF2C, CHRNB4, KMO]
GO:0086100;endothelin receptor signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;9.083926447120524;9.028936615729279E-4;0.7876727335416686;[EDNRB]
GO:0035094;response to nicotine;4.0;0.9326813400603323;0.7163406700301662;9.446202695698167;26.17342148764107;5.926926025970411;8.760008626412986E-4;0.5531032725983739;[CHRNB4, SLC7A11, CNR1]
GO:0051281;positive regulation of release of sequestered calcium ion into cytosol;13.0;0.8933024483968273;0.9092061889660501;9.585964638073326;905.0686146861244;6.139487467954083;0.03029183202467376;0.7765286393941734;[TRPC1, F2R, CD19, F2RL3]
GO:0043410;positive regulation of MAPK cascade;10.0;0.6634067003016617;0.7469443620117512;9.174268980214526;1017.2390743488962;3.4929394666096676;0.03404607636272706;0.5938700986216354;[, PROK2, EPHA3, FPR1, TGFA, FPR2, SLC30A10, IQGAP3, PDGFC, ELANE, CCR1, FZD5, MARCO, NOX4, CD24, EZH2, NRP1, CD36, MAP4K1, GPR37, FCRL3, DUSP6, BANK1, TLR4, CXCR4, GNAI2, GPNMB, PKN1, CTGF, PYCARD, MAP2K2, F2R, ADAM9, C5AR1, TNFRSF11A, DRD4, TGFB1, GH1, CSPG4, LRRK2, TREM2, GHR, CHI3L1, EGF, CD4, LTBR, TEK, FCGR2B]
GO:0006549;isoleucine metabolic process;8.0;0.8653626801206646;0.8076813400603323;9.503361109538115;166.53491036647193;8.16763571524637;0.00557377357827698;0.7926932703116032;[GHR]
GO:0007517;muscle organ development;4.0;0.7763722522362496;0.6381861261181248;8.753055515138222;27.682183388997124;5.085725745451326;9.264977656821302E-4;0.5100842511328143;[SGCE, BASP1, MEF2C, EGR3, HBEGF]
GO:0097113;AMPA glutamate receptor clustering;9.0;1.0;0.896240625180289;9.628524252492122;45.884964450884205;8.390779266560578;0.0015357284663841083;0.8253454670833372;[NLGN1]
GO:0097115;neurexin clustering involved in presynaptic membrane assembly;7.0;1.0;0.8509193652572005;9.628524252492122;44.498670089768545;9.777073627680469;0.001489330441701492;0.8509193652572005;[NLGN1]
GO:0097114;NMDA glutamate receptor clustering;8.0;1.0;0.875;9.628524252492122;45.884964450884205;8.390779266560578;0.0015357284663841083;0.8041048419030481;[NLGN1]
GO:0097119;postsynaptic density protein 95 clustering;6.0;1.0;0.8231203125901445;9.628524252492122;32.82490209968103;7.9853141584524145;0.0010986199327823658;0.7314896500084853;[NLGN1, LRRC4]
GO:0010800;positive regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;778.6672313762616;6.375876246018314;0.026061291479152104;0.7413036195908642;[TGFB1, EGF, AZU1, CHI3L1]
GO:2001199;negative regulation of dendritic cell differentiation;8.0;1.0;0.875;9.628524252492122;349.4674446787805;7.9853141584524145;0.01169636087311766;0.7833693374183408;[TMEM176B, TMEM176A, LILRB1, FCGR2B]
GO:0014049;positive regulation of glutamate secretion;9.0;0.8933024483968273;0.8428918493787028;9.587702257971866;414.8970628992697;7.474488534686424;0.013886231312124032;0.7784863164434164;[AVPR1A, KMO]
GO:0042976;activation of Janus kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1439.1116520623075;8.16763571524637;0.04816577187812465;0.8658135829017477;[GHR]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[IL5RA, SLA2, FGF5, GRAP2, MAP2K2, BTC, MELK, BTK, EPHA3, BLK, CSF2RB, LYN, BMX, PTK2, GHR, HBEGF, EGF, WEE1, TEK]
GO:1902476;chloride transmembrane transport;8.0;1.0;0.875;9.628524252492122;110.5175749436453;5.311165509025885;0.0036989237740038075;0.6466132511260384;[GABRB1, SLC1A3, GABRE, CLCA4, GABRA5, SLC12A1, CLDN4, SLC26A8, SLC26A7, CLDN17, SLC26A3]
GO:1902474;positive regulation of protein localization to synapse;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;25.478761436601122;7.8311634786251565;8.527512158864491E-4;0.7236063770733796;[NLGN1]
GO:1902358;sulfate transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;123.29733532969695;7.069023426578259;0.0041266508530873195;0.7365101867784198;[SLC13A1, SLC26A8, SLC26A7, SLC26A3]
GO:0008543;fibroblast growth factor receptor signaling pathway;8.0;0.7090535922965819;0.729526796148291;8.567652291806858;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[CTGF, FGF5, FLRT2, KIF16B]
GO:1903206;negative regulation of hydrogen peroxide-induced cell death;9.0;0.8436909121759173;0.8180860812682478;9.589303539338841;500.078557460717;6.8867018697843045;0.01673717927672765;0.7484268790654467;[GPR37, LRRK2]
GO:0006006;glucose metabolic process;6.0;0.7090535922965819;0.6776471087384355;8.572471578242808;34.676020684410545;5.040875179285974;0.0011605752059146955;0.5809109036834981;[HK3, AKT1, NPY1R, FBP1, ATF3]
GO:0008306;associative learning;7.0;0.8436909121759173;0.7727648213451592;9.223059144383958;22.449675191779697;5.459585514144159;7.513704252729093E-4;0.6301228223472235;[NRGN, TNR, GABRA5, MEIS2, ADAM2]
GO:0007217;tachykinin receptor signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;7.697632086000634;9.028936615729279E-4;0.7167775754447168;[TACR3]
GO:0007214;gamma-aminobutyric acid signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;6.558197802812269;9.028936615729279E-4;0.6585068532133508;[GABBR1, GABRB1, GABRA5, GABRE, GNAI2]
GO:0009755;hormone-mediated signaling pathway;5.0;0.6519675769143192;0.6162248003180799;7.98629651723503;23.17027026302992;4.61801832846594;7.75488093814194E-4;0.5264066839384828;[NR3C2, NUP62, GHSR, LHCGR, ACSL1, CCNE1, PADI2, NR1H2, DEFA1, TSHR, NR4A2, NR4A1, RAN, LGR4]
GO:0007207;phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;80.58987167142863;7.9853141584524145;0.00269727047866701;0.7833693374183408;[CHRM2, CHRM1]
GO:0010977;negative regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;494.1264199049594;4.793467005972133;0.016537966589312465;0.6413787507847162;[NRP1, LRRK2, TNR, DCC, NLGN1, LRP1, LINGO1, PLK2, SEMA4B, PTK2, ITM2C]
GO:0048169;regulation of long-term neuronal synaptic plasticity;9.0;0.8933024483968273;0.8428918493787028;9.461470167828956;42.75619717690252;6.481236761676141;0.0014310114414316764;0.7276913745807394;[GRM5]
GO:0098655;cation transmembrane transport;6.0;0.518007056267642;0.5821238407239655;7.133254815668575;43.36096628843346;3.3345334612122706;0.0014512525193377528;0.4936485088682041;[SCN1A, SLC6A16, SLC11A1, SLC6A15, CACNA2D3, KCNQ1, SLC22A4, SLC30A10, KCNMB3, KCNN3, SCN3A, SLC6A6, KCND2, TMEM37, KCNG2, STEAP4, DENND5B, SLC8A1, KCNH1, F2R, ATP1B2, ATP1B1, KCNE3, KCNE4, HVCN1, SLC41A2, SLC1A3, KCNK5, ATP2A3, SLC40A1, SLC36A1, TRPC7, SLC13A1, TRPC1, SLC24A1, SLC24A4, SLC12A1, KCNJ15, KCNJ16, P2RX5, P2RX1]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[CELSR1, CDH3, AP2M1, TLE4, CCNE1, PFN1, APCDD1, FZD5, NR4A2, VANGL1, SDC1, CD24, CDK14, LRRK2, HHEX, AES, EGF, LGR4]
GO:0010976;positive regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;493.1928131726474;4.231896183200907;0.016506719612173492;0.6126599927924817;[SCARB2, CYFIP1, CPNE5, PLXND1, EPHA3, LYN, SYT2, EZH2, ROBO2, NRP1, NLGN1, CNR1]
GO:0060291;long-term synaptic potentiation;8.0;1.0;0.875;9.628524252492122;145.7697243391103;5.948432231191374;0.004878781489395318;0.6792031009335148;[SLC24A1, NLGN1, PLK2, TNR]
GO:0060292;long term synaptic depression;8.0;1.0;0.875;9.628524252492122;145.80791725818347;7.004484905440688;0.004880059772025301;0.7332096838060964;[SLC24A1, PLK2]
GO:0048041;focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;92.53238439646684;6.599019797332524;0.0030969756320103773;0.712474179321389;[ACTN1, PTPRK, ARHGAP6]
GO:0061364;apoptotic process involved in luteolysis;6.0;1.0;0.8231203125901445;9.628524252492122;51.78173534202254;8.67846133901236;0.0017330880813612496;0.7669372290569613;[ROBO2]
GO:0060396;growth hormone receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.292166977892469;0.0010376185600805164;0.747921758369865;[GHR, GH1, PTK2]
GO:0060397;JAK-STAT cascade involved in growth hormone signaling pathway;8.0;1.0;0.875;9.628524252492122;26.42836680105094;7.212124270218933;8.845336528452411E-4;0.7438283705770736;[LYN, GHR, GH1, PRL]
GO:0061002;negative regulation of dendritic spine morphogenesis;12.0;1.0;0.9481203125901445;9.628524252492122;1979.5057838953023;7.9853141584524145;0.06625227714743111;0.8564896500084854;[NLGN1]
GO:0060155;platelet dense granule organization;6.0;1.0;0.8231203125901445;9.628524252492122;22.861654980906852;7.697632086000634;7.651590180572567E-4;0.7167775754447168;[ABCA1, F2R, F2RL3]
GO:0006259;DNA metabolic process;6.0;0.44800904580126355;0.5471248354907763;7.116218628516007;145.2579376122707;3.086231350261906;0.004861652448226147;0.4809503273669734;[EHMT2, SLBP, BARD1, CDC6, EZH2, CHAF1B, CHAF1A, RMI1, UNG, GTF2H1, CTGF, RUVBL1, MSH6, MSH2, BLM, MCM7, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, SMC1A, DBF4, MCM3, MCM4, MCM6, MCM2, RBBP8, RAD51, CCNH, CHEK1, ESCO2, ERI2, BCL11B, POLA1, POLA2, BRCA2, CCR6, RAD51C, PCNA, PRIM1, RAD54B, NT5E, RPA1, MLH1, RPA3, DCLRE1A, CCNE1, HMGA1, NASP, HMGB2, TOPBP1, POLD3, POLD1, POLE2, SSBP1, RAN]
GO:0042985;negative regulation of amyloid precursor protein biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;967.9208223894049;7.9853141584524145;0.032395438853188026;0.8046099625986299;[ITM2A, ITM2C]
GO:0098664;G-protein coupled serotonin receptor signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;51.24581530449654;6.599019797332524;0.0017151513200019748;0.6605944919115335;[HTR1E]
GO:0007218;neuropeptide signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;5.123113277522946;9.028936615729279E-4;0.5851165638517994;[SORT1, NPY1R, GPR84, SORCS3, PNOC, PROK2, GPR19]
GO:0051453;regulation of intracellular pH;10.0;0.7192862368539868;0.7748841302879137;9.242861771680136;143.07278219841277;5.407625775213448;0.004788517263036519;0.6917872454856517;[LRRK2, SLC11A1, AVPR1A, SLC4A7, SLC26A8, SLC26A7, SLC26A3]
GO:0007219;Notch signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.50247477320489;4.99795013456894;8.87013979980389E-4;0.5787157149004503;[TMEM100, HHEX, FCER2, PSEN2, S1PR3, TGFB1, JAG1, KRT19]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, IQGAP3, JAG1, JUP, AZU1, MMP12, PTAFR, ATAD2, LGR4, CTGF, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, CD28, BRCA2, CD3E, CD36, CCNE1, CAV1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, EGF, CD4, RAN, EHF, MYB, NUP85, NFE2, FZD5, PAWR, PAX5, ENG, EPCAM, GSN, NR1H2, GTF2H1, PLP1, PLXND1, CDH3, CDH1, MAP2K2, F2R, ADAM2, MAFF, RFC1, CEBPE, KLF5, CHEK1, SLC11A1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, CAMK4, ARID4A, HGS, STAP1, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0016042;lipid catabolic process;4.0;0.5127202928476964;0.5063601464238482;6.883086519318291;43.14795622097559;4.114113147544524;0.0014441232640765526;0.4603959376912539;[ABHD12, SLC27A2, PLD4, PLA2G7, CYP4F2, CYP4F3, SRD5A3, PNPLA6]
GO:0019432;triglyceride biosynthetic process;8.0;1.0;0.875;9.628524252492122;411.96489591296563;6.832634648514029;0.013788094321871398;0.7244212536750128;[DGAT2, ACSL1, MOGAT2]
GO:0048290;isotype switching to IgA isotypes;13.0;1.0;0.9625549647676366;9.628524252492122;268.78471588944643;9.777073627680469;0.008995982550280335;0.9625549647676366;[CCR6]
GO:0019674;NAD metabolic process;10.0;0.7369933605727446;0.7837376921472926;9.33127272902419;293.8575721815232;5.54296712308321;0.009835148486270468;0.6987086083097278;[PTGS2, HK3, NT5E, KMO, BST1]
GO:0072139;glomerular parietal epithelial cell differentiation;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;51.0109489693332;9.083926447120524;0.0017072905551300363;0.8154717862087246;[CD24]
GO:0032870;cellular response to hormone stimulus;5.0;0.6039883530135606;0.5922351883677006;7.932074963068391;80.94247679971589;3.9540277321974506;0.0027090718549867714;0.49245017396659174;[CYFIP1, PID1, AKT1, GHSR, LHCGR, MEF2C, POR, ADCY9, SIK1, ABCB4, SLC30A10, FOXO1, PRKAR2B, IGFBP7, GAS2L1, TGFB1, CAV1, CDC6, INHBA, NR4A2, NR4A1, ROBO2, CTSS, GHR, DUSP1, ARG1, GLP2R, AVPR1A, CEACAM1, P2RY6, TSHR, RAMP1]
GO:0010744;positive regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;113.85781812010546;7.004484905440688;0.0038107187070962377;0.6813299963962409;[MSR1, AGTR1, CD36]
GO:0031666;positive regulation of lipopolysaccharide-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;344.2408759115043;7.697632086000634;0.011521432320083432;0.7445766281117727;[CD180, LY96]
GO:0033602;negative regulation of dopamine secretion;9.0;1.0;0.896240625180289;9.628524252492122;383.5961800611833;8.67846133901236;0.012838618932498951;0.8400575416471059;[CNR1]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[DACH1, MEF2C, PADI2, TACSTD2, STAP1, TGFB1, JAG1, JUP, GPR18, PTPRR, MCTP1, PTPRK, ARAP3, TMEFF2, ENG, LRP1]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[LGALS3, C3AR1, AKT1, IL1R1, ACTN4, PFN1, FPR2, PLA2G7, PDGFC, ELANE, LYN, CCR1, PLK2, PTK2, NOX4, NRP1, NRP2, CCR6, CCR2, ANXA3, GAB1, CEACAM6, HBEGF, PTAFR, PTGS2, GNAI2, GPNMB, CXCR2, PDPN, FLNA, SLC8A1, CXCL16, PYCARD, IL6R, F2R, ADAM9, CD274, CD151, C5AR1, CORO1A, TGFB1, DOCK5, TNFAIP6, LAMC2, CXCL1, CXCL2, MMP9, P2RY6, EGF, SEMA4B, TEK]
GO:0042759;long-chain fatty acid biosynthetic process;9.0;0.7980440201809971;0.7952626352707877;9.372590878354922;458.549617088559;6.375876246018314;0.015347243016091356;0.722303232910233;[PTGS2, ALOX5, PLP1]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[CAV1, PTAFR, F2R, AVPR1A, PTGS2, AKT1]
GO:1905520;positive regulation of presynaptic active zone assembly;9.0;1.0;0.896240625180289;9.628524252492122;390.905034801094;9.777073627680469;0.013083239723101546;0.896240625180289;[NLGN1]
GO:0006101;citrate metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.474373572664863;74.60362419578414;6.139487467954083;0.0024969161629301456;0.6648930398837374;[GHR]
GO:0038171;cannabinoid signaling pathway;6.0;0.8653626801206646;0.7558016526504768;9.4949928598676;26.976932752798508;8.16763571524637;9.028936615729279E-4;0.7408135829017477;[CNR1]
GO:1903589;positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis;9.0;1.0;0.896240625180289;9.628524252492122;341.3007332013115;7.57984905034425;0.01142302838952993;0.7838744581139225;[AGTR1]
GO:0003198;epithelial to mesenchymal transition involved in endocardial cushion formation;7.0;1.0;0.8509193652572005;9.628524252492122;26.141399598032546;7.379178354882098;8.749291188139309E-4;0.728290889492758;[TMEM100, ENG]
GO:0009615;response to virus;5.0;0.7436939687323844;0.6620879962271125;8.801845679307654;27.267803904038782;4.174954806800768;9.126288572378991E-4;0.503748394835965;[CHRM2, PYCARD, STMN1, IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, HMGA1, AZU1, DEFA1, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, MMP12, TLR8, TLR7, UNC93B1, CXCR4, SAMHD1, LILRB1]
GO:0006105;succinate metabolic process;7.0;0.811012628672052;0.7564256795932265;9.253830803050711;71.35146239328425;7.292166977892469;0.0023880692341560756;0.7238411236270654;[GHR]
GO:0042631;cellular response to water deprivation;6.0;0.9326813400603323;0.7894609826203107;9.587702257971866;306.78131104411256;8.67846133901236;0.01026769439539148;0.7669372290569613;[AVPR1A, SIPA1]
GO:0006469;negative regulation of protein kinase activity;10.0;0.6835726970475526;0.7570273603846966;9.223059144383958;1097.0598301796;4.243684138952949;0.03671760522636433;0.6322632160784685;[PYCARD, PPP2R1A, AKT1, TSC2, FLRT2, PRKAR2B, SFN, LYN, CAV1, PKIG, CDKN1A, LRRC4, HHEX, LRRTM4, NUP62, DUSP2, DUSP1, DUSP6, CEACAM1, LRRC19, CDKN2C, PKN1]
GO:0006103;2-oxoglutarate metabolic process;7.0;0.7980440201809971;0.7499413753476991;9.136047767394327;69.92434603764816;6.832634648514029;0.0023403049340542706;0.7003406189322132;[GHR]
GO:0030206;chondroitin sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;416.1007025877491;6.558197802812269;0.013926516049292044;0.7103865406232063;[CSPG4]
GO:0010839;negative regulation of keratinocyte proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;86.66714155745981;7.212124270218933;0.002900671232564666;0.7197477358342742;[SFN, PTPRK]
GO:0010718;positive regulation of epithelial to mesenchymal transition;6.0;0.811012628672052;0.7286266269261705;9.377209824211215;170.70262580884207;5.9928839937622085;0.005713263263432726;0.6295966787287501;[PDPN, TGFB1, EZH2, ENG]
GO:0010717;regulation of epithelial to mesenchymal transition;5.0;0.7140352122741334;0.6472586179979869;8.999915593069748;54.42428208907013;5.395046993006588;0.001821531742847262;0.5661439659786197;[PDPN, TGFB1, EPHA3, EZH2, ENG]
GO:0030208;dermatan sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;665.197598747091;7.292166977892469;0.022263564991093197;0.747921758369865;[CSPG4]
GO:0009968;negative regulation of signal transduction;6.0;0.43649654099988644;0.5413685830900877;6.680044863788677;140.65047919891595;2.686163805600486;0.0047074449615745265;0.460490854527945;[, PID1, SLA2, STMN1, AKT1, UBASH3A, PADI2, ATF3, FLRT2, FIGNL1, LYN, EZH2, LRRC4, DUSP2, DUSP1, ARG1, FCRL3, PAWR, DUSP6, AES, MMP12, LRRC19, PTGS2, NR1H2, SULF2, LGR4, PYCARD, TLE4, LY96, FOXO1, WFS1, TNFRSF10B, PTPRE, BCL6, CCDC22, LRRK2, HHEX, LRP1, LGALS3, PPP2R1A, IL1R2, RUNX2, SIK1, EPHA3, APCDD1, EGR1, VNN1, NRP1, PTPRR, CD3E, CEACAM1, BANK1, TLR4, GNAI2, NLRP12, GRINA, RGS1, TSC2, HGS, STAP1, NLRP3, TGFB1, CAV1, NR4A2, HMGB2, LRRTM4, NUP62, PTGIR, ARAP3, MMP9, DNM2, FBP1, LTF, CLEC12B, EGF, TEK]
GO:0030449;regulation of complement activation;8.0;0.6873818243518346;0.7186909121759173;9.298282565621545;245.7676390307622;5.076593261888053;0.008225621701844479;0.6346172154986847;[C5AR1, IGHG1, IGKC, CD19, IGLV1-44, C3AR1, CR2, CR1, IGKV3-20]
GO:0030207;chondroitin sulfate catabolic process;8.0;1.0;0.875;9.628524252492122;411.79540990145875;7.138016298065211;0.01378242177759377;0.7400384854347593;[CSPG4]
GO:0032740;positive regulation of interleukin-17 production;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;65.23665507211369;7.212124270218933;0.002183412136085803;0.6919486831672181;[TGFB1, LY9]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[LRRK2, CDH3, FZD5, EGF, NR4A2, SDC1, LGR4]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[NRP1, FLNA, CXADR, GAB1]
GO:0038044;transforming growth factor-beta secretion;10.0;1.0;0.9152410118609203;9.628524252492122;137.06961104194002;9.083926447120524;0.004587596526932657;0.8797934328124444;[ITGB6]
GO:0038043;interleukin-5-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[IL5RA, CSF2RB]
GO:0051480;regulation of cytosolic calcium ion concentration;10.0;0.6634067003016617;0.7469443620117512;9.01761517016915;288.6919123283276;4.053488525728088;0.009662258499776054;0.6225366035731486;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CD24, GPR18, GRM5, CCR9, CCR6, CD36, CCR2, TRPC7, CD52, PTGIR, TRPC1, AVPR1A, CXCR5, CXCR4, CXCR1, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, F2RL3]
GO:1904328;regulation of myofibroblast contraction;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;39.20935980508448;9.777073627680469;0.0013123019865433228;0.8231203125901445;[PDPN]
GO:0007202;activation of phospholipase C activity;9.0;1.0;0.896240625180289;9.628524252492122;83.73920694944017;6.444869117505266;0.0028026758962043192;0.7258315315665724;[C5AR1, AVPR1A, SELE, RASGRP4]
GO:0007200;phospholipase C-activating G-protein coupled receptor signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.976932752798508;5.288437257948329;9.028936615729279E-4;0.5935712398991049;[CHRM2, LHCGR, CHRM1, C5AR1, F2R, FPR1, FPR3, FPR2, GPR84, NMBR, MC3R, GRM5, P2RY6, EDNRB, P2RY2, CXCR2, C3AR1, AGTR1, F2RL3]
GO:0021965;spinal cord ventral commissure morphogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;69.80210411808247;8.67846133901236;0.002336213607016992;0.8762458687964789;[DCC]
GO:1905898;positive regulation of response to endoplasmic reticulum stress;7.0;0.7763722522362496;0.7391054913753253;9.136047767394327;86.77986502582442;6.166155715036245;0.002904443985606294;0.6662568552797195;[CAV1, FCGR2B, ATF3]
GO:0007569;cell aging;3.0;0.7980440201809971;0.597142322680643;8.935377071932177;24.751975343904395;5.618190544320798;8.284263394289076E-4;0.485434838299289;[CDKN1A, BRCA2, NUP62, CHEK1, MME, HMGA1, NOX4, ENG]
GO:0007206;phospholipase C-activating G-protein coupled glutamate receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;83.92207618159998;9.083926447120524;0.0028087963648330836;0.839552420951524;[GRM5]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CD24, GPR18, CCR9, CCR6, CD36, CCR2, CD52, PTGIR, TRPC1, AVPR1A, CXCR5, CXCR4, CXCR1, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, F2RL3]
GO:0030318;melanocyte differentiation;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;22.857985252022832;6.8867018697843045;7.650361955340501E-4;0.6424272657460779;[MEF2C, EDNRB]
GO:0006107;oxaloacetate metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.36615998802463;49.228254352165074;7.292166977892469;0.0016476253706144133;0.7238411236270654;[GHR]
GO:0009617;response to bacterium;5.0;0.7508913569872202;0.6656866903545304;8.935377071932177;27.267803904038782;3.9481280100702625;9.126288572378991E-4;0.49214846190264216;[, HP, PYCARD, IGHG1, IL6R, SLC11A1, RNASE6, RNASE3, CHIT1, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, NLRP3, IGHA1, ELANE, DEFA4, CAV1, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, HMGB2, CTSG, CD36, CAMP, ANXA3, TLR1, IGHD, BPI, TLR5, TLR4, LTF, TLR2, CEBPE, HIST1H2BK, PTAFR, NLRC4, IGKC, CD4, FCGR2B]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CXCR5, CXCR4, CXCL1, CXCL2, CXCR1, CXCR2, CCRL2, CCR9, CCR6, CCR10, CCR2, CCR1]
GO:0016264;gap junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;56.140948375987016;7.8311634786251565;0.001878987018571015;0.7236063770733796;[GJC1, GJB2]
GO:0019530;taurine metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.405380701177911;107.69553235458599;7.8311634786251565;0.0036044725482214327;0.6907270763441554;[GHR]
GO:0010841;positive regulation of circadian sleep/wake cycle, wakefulness;6.0;1.0;0.8231203125901445;9.628524252492122;109.56266212983566;8.390779266560578;0.0036669637014913365;0.7522251544931926;[NLGN1]
GO:0019532;oxalate transport;9.0;0.9326813400603323;0.8625812952104552;9.541512875502493;53.14108600855652;7.292166977892469;0.0017785843248339678;0.769162383550154;[SLC26A8, SLC26A7, SLC26A3]
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[HMGB2, LHCGR, BIK, INHBA, NASP, MSH2]
GO:0032693;negative regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.943860283624253;0.002184000309729388;0.6782296504172152;[CD274, PRG2, LILRB1, PDCD1LG2, FCGR2B]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[GABRB1, TGFB1, CAV1, CLDN4, TLR2]
GO:0046854;phosphatidylinositol phosphorylation;8.0;1.0;0.875;9.628524252492122;218.7418113453505;5.049685808968129;0.007321091570879569;0.6332411671050352;[SLA2, FGF5, IMPA2, GAB1, BTC, HBEGF, CD19, TRAT1, EGF, CD28]
GO:0045762;positive regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6276.064729494611;7.697632086000634;0.21005423840463325;0.8417775754447168;[LHCGR, TSHR]
GO:0008344;adult locomotory behavior;3.0;0.8436909121759173;0.6199657686781032;9.158520623246385;24.575257889458463;5.459585514144159;8.225117652639858E-4;0.47732376968016754;[ABHD12, CHL1, SLITRK6, DRD4, SCN1A, NR4A2]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, GHSR, ANXA3, GAB1, ADAM12, AGTR1, CHI3L1, ENG, C5AR1, PTGS2, CXCR2, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0001942;hair follicle development;4.0;1.0;0.75;9.628524252492122;22.36266381479647;6.166155715036245;7.48458232790436E-4;0.5653374900225189;[INHBA, CELSR1, APCDD1, LGR4]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, FLNA, NR1H2, LGR4, GMNN, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, EDNRB, RUNX2, PCBP3, EGR1, BCL11A, IFNA2, PTPRK, XPO1, CD36, ARID4A, BASP1, CCNE1, TGFB1, CBX4, CAV1, HMGA1, NR4A2, MXD1, HMGB2, FBP1, MEIS2]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[MSH2, MAFF, PTPRR, TMEM100, HHEX]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, JAG1, JUP, MMP12, ATAD2, LGR4, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, CD28, BRCA2, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, EGF, CD4, RAN, EHF, MYB, NUP85, NFE2, FZD5, PAX5, ENG, EPCAM, NR1H2, GTF2H1, PLXND1, CDH1, MAP2K2, F2R, MAFF, RFC1, CEBPE, KLF5, CHEK1, SLC11A1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, CAMK4, ARID4A, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0001946;lymphangiogenesis;3.0;1.0;0.6981203125901445;9.628524252492122;22.057452475282865;7.292166977892469;7.382430839292881E-4;0.5710420709600095;[PDPN]
GO:0046629;gamma-delta T cell activation;6.0;0.7866048967936545;0.7164227609869718;9.176539128749065;21.64461009501914;7.8311634786251565;7.244256209958813E-4;0.7236063770733796;[CXADR, CCR9, GPR18]
GO:0071805;potassium ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.456673995565463;120.6235085317852;4.695669262696007;0.004037160276449102;0.636377369645515;[KCNK5, KCNG2, KCNE3, KCNE4, SLC1A3, KCNMB3, KCNN3, KCNH1, KCND2, SLC12A1, KCNJ15, KCNJ16, ATP1B2, ATP1B1, KCNQ1]
GO:0007268;chemical synaptic transmission;7.0;0.7369933605727446;0.7194160455435727;8.663443356448536;23.173347188538074;3.922001705478042;7.755910757418987E-4;0.5514907148670789;[CHRM2, GABRB1, CHRM1, GRM5, CHRNB4, KCND2, NPY1R, SLC5A7, SLC1A3, GJC1, SV2A, HRH4, KCNMB3, SLC17A6, GABRE, DRD4, EGR3, HTR1E, GABRA5, PCDHB15, PCDHB14, PCDHB10, P2RX1, PNOC, PCDHB16, PLP1, PCDHB4, PCDHB8, GPR19]
GO:0007266;Rho protein signal transduction;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;29.60642063139588;5.334422371190153;9.9090025448413E-4;0.6478026081386739;[CELSR1, ARHGAP6, PDPN, EPS8L1, RHOG, BCL6, AGTR1, RHOU]
GO:0008354;germ cell migration;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;40.540081573954176;7.57984905034425;0.0013568400465755524;0.6778748447945537;[TGFB1, CXADR]
GO:2000809;positive regulation of synaptic vesicle clustering;7.0;1.0;0.8509193652572005;9.628524252492122;59.688833127145365;8.16763571524637;0.001997731528303309;0.7686126355688037;[NLGN1]
GO:0007269;neurotransmitter secretion;8.0;0.7043150770688792;0.7271575385344395;8.771074020640901;61.60461712537578;6.113511981550823;0.00206185109463042;0.6876452870438905;[SLC5A7, LIN7A]
GO:0002922;positive regulation of humoral immune response;6.0;0.6997970393407541;0.6730188322605215;9.0306872517365;108.8065326900253;7.069023426578259;0.0036416567296131998;0.6846304993685643;[FCER2, FCGR2B]
GO:0002924;negative regulation of humoral immune response mediated by circulating immunoglobulin;10.0;0.8933024483968273;0.861892236059334;9.592156608321247;508.9965303178644;7.9853141584524145;0.017035655802601874;0.8236103492792612;[CR1, FCGR2B]
GO:0014902;myotube differentiation;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;22.452520143917486;7.379178354882098;7.514656432606705E-4;0.7004918368257019;[MEF2C, SORT1, AVPR1A]
GO:0032430;positive regulation of phospholipase A2 activity;8.0;0.8933024483968273;0.8216512241984136;9.5544162803384;83.73920694943958;7.9853141584524145;0.0028026758962042993;0.7833693374183408;[AGTR1]
GO:0033762;response to glucagon;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;6.166155715036245;0.0024778305216419678;0.6662568552797195;[ARG1, ABCB4, GLP2R, ADCY9, PRKAR2B]
GO:0001959;regulation of cytokine-mediated signaling pathway;6.0;0.6108066114563391;0.628523618318314;8.112176763124033;55.1119710577094;4.759793790865545;0.0018445480737477274;0.5665363884080561;[PYCARD, IL1R1, IL1R2, PADI2, STAP1, CAV1, CD24, TREM2, ARG1, MMP12, NR1H2]
GO:0086097;phospholipase C-activating angiotensin-activated signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;56.726454227837834;9.083926447120524;0.001898583372511406;0.8154717862087246;[AGTR1]
GO:0034614;cellular response to reactive oxygen species;5.0;0.7671156992804218;0.6737988615011312;9.197741336399668;144.094088465717;5.076593261888053;0.004822699464687224;0.5498582273596049;[PTPRK, IL18RAP, MYB, AKT1, ARG1, MMP9, DNM2, BTK, PCNA, FOXO1, EZH2]
GO:0031103;axon regeneration;7.0;0.8436909121759173;0.7727648213451592;9.427853557029971;96.50678923292918;6.832634648514029;0.00322999538515464;0.7003406189322132;[CHL1, JAM3]
GO:0070507;regulation of microtubule cytoskeleton organization;7.0;0.6073376606709605;0.6545881955926808;8.242229891372231;33.71079736555127;4.584116776790259;0.0011282700500770656;0.5853513104054853;[STMN1, CHEK1, EPHA3, PLK2, XPO1, NUP62, CKAP2, SMC1A, PSRC1, GNAI1, RANBP1]
GO:0007597;blood coagulation, intrinsic pathway;6.0;1.0;0.8231203125901445;9.628524252492122;55.78978942234946;6.943860283624253;0.0018672340444153065;0.6782296504172152;[GP1BB, GP5]
GO:0045786;negative regulation of cell cycle;5.0;0.5089359064165209;0.5447089650691808;7.0970975870692286;42.34575940812408;3.5270983854209863;0.0014172744586806725;0.47061698731819834;[EHMT2, CHEK1, FBXO5, SFN, BARD1, PLK2, CDC6, ZWINT, EZH2, CDKN1A, PTPRK, BRCA2, DUSP1, PCNA, PTGS2, GPNMB, CDKN2C, LILRB1, SIPA1, GMNN, KNTC1, MSH6, MSH2, BLM, NACC2, GAS2L1, TGFB1, DHCR24, INHBA, NR4A1, BCL6, CNOT3, HHEX, TOPBP1, SMC1A, RBBP8, BUB1, E2F7, WEE1, RAD51]
GO:0044332;Wnt signaling pathway involved in dorsal/ventral axis specification;8.0;1.0;0.875;9.628524252492122;31.415129658942366;7.9853141584524145;0.0010514361179036673;0.7833693374183408;[FZD5, EGF]
GO:0007595;lactation;6.0;1.0;0.8231203125901445;9.628524252492122;25.956233089099676;5.9928839937622085;8.687317623989867E-4;0.6295966787287501;[ABCB4, CAV1, PRL]
GO:0097193;intrinsic apoptotic signaling pathway;6.0;0.7436939687323844;0.6949672969563367;9.0689084645567;50.98493142520191;4.74012102526684;0.0017064197713422317;0.5655303222604612;[PYCARD, MSH6, MELK, MSH2, LGALS12, SFN, TNFRSF10B, CD24, CDKN1A, BRCA2, TNFRSF1B, MLH1]
GO:0097192;extrinsic apoptotic signaling pathway in absence of ligand;7.0;1.0;0.8509193652572005;9.628524252492122;76.30875120206336;6.375876246018314;0.0025539852293156346;0.6769819729871445;[DCC]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[CYFIP1, CD3G, IGHG1, FCGR3A, IGKC, IGLV1-44, LYN, PTK2, FCGR2A, FCGR2B, IGKV3-20]
GO:0043491;protein kinase B signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.250713103064308;8.845336528452411E-4;0.6427820713687392;[TGFB1, TSC2, TMEM100, AKT1]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[NRP1, ITGAM, ITGB4, CTGF, ITGB6, CEACAM1, ADAM9, TLN1, PTK2, ZYX, PLP1, LAT]
GO:0097068;response to thyroxine;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;148.64568421023415;8.16763571524637;0.004975037278085989;0.7408135829017477;[ABCB4]
GO:0035815;positive regulation of renal sodium excretion;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;135.61946749691032;7.069023426578259;0.004539061527524972;0.7365101867784198;[EDNRB, AVPR1A, GNAI2]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, FLRT2, HLA-DQA1, HLA-DRB4, CDKN1A, LRRC4, HLA-DPA1, FCER2, HLA-DQB1, LRRC19, PTAFR, PTGS2, ALOX5, HLA-DPB1, CSF3R, F13A1, IL5RA, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, BCL6, LCN2, HLA-DRA, CIITA, ITGAM, TNFRSF1B, FCGR1B, ACSL1, IL1R1, IL1R2, CCR10, CCR1, EGR1, TNFSF12, SDC1, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR6, CD36, CCR2, IL17RB, CEACAM1, RHOU, CXCR5, CXCR4, CXCR1, CXCR2, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, CXCL1, CXCL2, GHR, LRRTM4, MMP9, SAMHD1, CD4, LTBR]
GO:0045670;regulation of osteoclast differentiation;8.0;0.8259837884571596;0.7879918942285797;9.485423408851448;139.67875005531917;5.587418885654044;0.0046749220616377945;0.6607408616538982;[CCR1, LHCGR, LILRB1, LILRB3, CAMK4, TLR4, LTF]
GO:0010633;negative regulation of epithelial cell migration;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;243.45111910585655;5.602686357784832;0.008148089864690466;0.6615216408886768;[PTPRR, TACSTD2, MEF2C, TGFB1, JUP]
GO:0035813;regulation of renal sodium excretion;7.0;0.8436909121759173;0.7727648213451592;9.461470167828956;57.69104555789675;6.686031174322154;0.0019308673762526412;0.692843310444282;[EDNRB, AGTR1, AVPR1A, GNAI2]
GO:0032782;bile acid secretion;9.0;1.0;0.896240625180289;9.628524252492122;69.42950734212523;8.16763571524637;0.002323743128241031;0.8139338954918922;[ABCB4]
GO:0010634;positive regulation of epithelial cell migration;8.0;0.7866048967936545;0.7683024483968273;9.383401794459138;242.52723865374625;4.901876304479318;0.00811716841739676;0.6256821821716325;[DOCK5, NRP1, NRP2, AKT1, CCR6, ANXA3, MMP9, ADAM9, PFN1, HBEGF, PTGS2, TGFB1, PLK2, TEK]
GO:0019227;neuronal action potential propagation;6.0;1.0;0.8231203125901445;9.628524252492122;26.361698197207048;7.8311634786251565;8.823023146724341E-4;0.7236063770733796;[SCN1A]
GO:0019226;transmission of nerve impulse;4.0;1.0;0.75;9.628524252492122;26.01624213687652;6.943860283624253;8.70740211223441E-4;0.6051093378270707;[JAM3]
GO:0010873;positive regulation of cholesterol esterification;8.0;1.0;0.875;9.628524252492122;190.88116845363626;7.57984905034425;0.006388620926244623;0.7626338329336335;[AGTR1]
GO:0019229;regulation of vasoconstriction;7.0;0.7369933605727446;0.7194160455435727;9.310070521373587;55.827436365827396;5.500407508664414;0.0018684940537334635;0.6322104610454062;[DOCK5, CHRM1, PTAFR, PTGS2, AKT1, ACE, CAV1, F2R, AVPR1A, P2RX1, AGTR1]
GO:0035810;positive regulation of urine volume;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;23.90496242438734;7.138016298065211;8.000775792748091E-4;0.6552794972956795;[BTC, EDNRB, GNAI2]
GO:0042045;epithelial fluid transport;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;24.0554433753243;7.697632086000634;8.051140412786058E-4;0.6838982747154925;[EDNRB]
GO:0021891;olfactory bulb interneuron development;7.0;1.0;0.8509193652572005;9.628524252492122;36.71755479978741;8.390779266560578;0.0012289035154949403;0.7800242071602487;[ROBO2]
GO:0001811;negative regulation of type I hypersensitivity;11.0;1.0;0.9324289523296623;9.628524252492122;1110.322083208406;9.777073627680469;0.03716148089998564;0.9324289523296623;[FCGR2B]
GO:0042053;regulation of dopamine metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.446202695698167;57.43424041378585;6.781341354126479;0.001922272339188874;0.6977174774718518;[NR4A2, ITGAM, GPR37, TACR3, DRD4]
GO:0001934;positive regulation of protein phosphorylation;9.0;0.5833093054345528;0.6878952778975655;8.604019935977734;663.1129447749842;2.9039097934679514;0.02219379349871355;0.5447467070638558;[, AKT1, PROK2, FPR1, FPR2, SLC30A10, IQGAP3, PRKAR2B, PDGFC, ELANE, LYN, ACE, FZD5, CDC6, AZU1, NOX4, EZH2, CDKN1A, GPR37, FCRL3, DUSP6, HBEGF, ENG, PTGS2, GPNMB, PKN1, CTGF, PYCARD, IFNA14, MAP2K2, IFNA16, F2R, ADAM9, IFNA10, TNFRSF11A, DRD4, IFNA21, TNFRSF10B, CSPG4, LAT, LRRK2, TREM2, FCGR2B, CCNH, TCL1A, EDNRB, ACSL1, SLC11A1, EPHA3, TGFA, CCR1, EGR1, PTK2, MARCO, CD24, IFNA5, IFNA4, NRP1, IFNA7, IFNA2, CD3E, IFNA8, CD36, MAP4K1, BANK1, TLR4, CXCR4, GNAI2, IL6R, C5AR1, STAP1, TGFB1, CAV1, INHBA, GH1, GHR, GRM5, MMP9, PSRC1, CHI3L1, LTF, EGF, CD4, LTBR, TEK]
GO:0016064;immunoglobulin mediated immune response;6.0;0.7586651285174919;0.7024528768488905;9.040737587590003;30.584352397600135;7.069023426578259;0.0010236307506175364;0.6846304993685643;[EXO1, TLR8, FCGR2B, IL13RA2, HLA-DQB1]
GO:0001814;negative regulation of antibody-dependent cellular cytotoxicity;13.0;1.0;0.9625549647676366;9.628524252492122;1597.8162410140733;9.777073627680469;0.05347747164548317;0.9625549647676366;[FCGR2B]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CSF3R, C5AR1, CXCL1, CXCL2, LGALS3, CXCR1, CXCR2, CXADR, S100A8]
GO:0086072;AV node cell-bundle of His cell adhesion involved in cell communication;6.0;1.0;0.8231203125901445;9.628524252492122;24.262698198658363;9.777073627680469;8.120506736983656E-4;0.8231203125901445;[CXADR]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, CXCL16, VPREB3, LGALS3, VPREB1, EDNRB, C3AR1, IL6R, SLC16A3, CD177, CXADR, ATP1B2, ATP1B1, PRTN3, S100A8, GYPA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, IGLV1-44, IGHA1, ELANE, LYN, CCR1, TGFB1, GPR15, CAV1, TNFRSF10B, AZU1, DEFA1, SELE, SDC1, IGKV3-20, IGHM, ITGAM, CXCL1, SLC7A11, CXCL2, TREM1, OLR1, FFAR2, CCR6, CCR2, MMP9, CEACAM1, SLC7A7, SLC7A8, CEACAM6, PECAM1, CXCR5, CXCR4, IGKC, CXCR1, EPCAM, CXCR2, CD58, JAM2, JAM3, CD2, NLRP12, TEK]
GO:0030595;leukocyte chemotaxis;6.0;0.6873818243518346;0.6668112247660618;8.768322987269011;62.06300720445581;4.857092701852345;0.002077192998052941;0.5715122592407831;[CSF3R, CXCL1, CXCL2, CXCL16, LGALS3, EDNRB, FFAR2, CCR6, IL6R, CCR2, CXADR, S100A8, C5AR1, CXCR5, CXCR4, TNFRSF11A, CORO1A, CXCR1, NUP85, CXCR2, CCR1, AZU1, DEFA1]
GO:0010524;positive regulation of calcium ion transport into cytosol;12.0;0.811012628672052;0.8536266269261705;9.4949928598676;446.85811756486936;5.825829909099042;0.01495593904869991;0.7460535250702665;[CD19, CAV1, TRPC1, F2R, P2RX5, CD4, F2RL3]
GO:0017158;regulation of calcium ion-dependent exocytosis;9.0;0.6799073451904818;0.73619429777553;8.730582659286164;63.43514412564899;5.514393750639154;0.0021231171859622203;0.6782469780335098;[NLGN1, LRRK2, GNAI2, SYT2]
GO:0001819;positive regulation of cytokine production;5.0;0.5089359064165209;0.5447089650691808;6.969264215559344;44.25546033084785;3.8109268885567773;0.001481190429944989;0.48513199016793795;[MYB, C3AR1, SLC11A1, HHLA2, LY9, ELANE, EGR1, FZD5, PRG2, AZU1, CD28, ORM1, CD3E, FFAR2, CD36, CCR2, HLA-DPA1, NFAM1, IL17RB, MMP12, TLR1, IGHD, TLR8, TLR7, TLR5, TLR4, TLR2, PTAFR, PTGS2, CD58, LILRB2, SULF2, NLRP12, HLA-DPB1, CD83, PYCARD, CLEC5A, IL6R, F2R, CD274, C5AR1, LY96, NLRP3, TGFB1, LRRK2, HMGB2, CD2, CD4]
GO:0033864;positive regulation of NAD(P)H oxidase activity;6.0;1.0;0.8231203125901445;9.628524252492122;95.10874301741602;7.8311634786251565;0.0031832040364813217;0.7236063770733796;[AGTR1, GNAI2]
GO:0010460;positive regulation of heart rate;8.0;0.7763722522362496;0.7631861261181248;9.249034630787218;94.35920462208708;6.641579411751319;0.003158117660930423;0.7146506799819907;[KCNQ1, TACR3, AVPR1A]
GO:0007171;activation of transmembrane receptor protein tyrosine kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1143.6879814690685;7.212124270218933;0.03827820748741112;0.8169486831672182;[EGF, PDGFC]
GO:1903169;regulation of calcium ion transmembrane transport;8.0;0.6260725219892441;0.688036260994622;8.50005900067433;58.212370637888874;4.835431205071165;0.001948315657517866;0.6222841766978864;[SLC8A1, TRPC1, F2R, ATP1B1, GEM, KCNE3, CORO1A, CD19, DRD4, LYN, TGFB1, TSPAN13, F2RL3]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[TGFA, SLC30A10, REPS2, AKT1, TGFB1, EGF, GAB1, PTK2, BTC, KIF16B, HBEGF]
GO:0061098;positive regulation of protein tyrosine kinase activity;11.0;0.8436909121759173;0.8542744084176208;9.55953138100517;2154.6219316186807;5.8650506222523235;0.07211325701743153;0.7323679139043926;[TGFA, GRM5, STAP1, ACE, EGF, CD24]
GO:0007179;transforming growth factor beta receptor signaling pathway;8.0;0.7586651285174919;0.754332564258746;9.05316010758856;29.903672154863813;5.2552850506314295;0.0010008489954655988;0.6437555218850388;[PTPRK, CDH5, ADAM9, TGFB1, PTK2, ZYX]
GO:0045720;negative regulation of integrin biosynthetic process;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;213.14924750076642;9.083926447120524;0.007133913491982032;0.8154717862087246;[TMEFF2]
GO:0051291;protein heterooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;5.113634533568402;0.00140677858073304;0.5846318204451575;[NUP62, CHRNB4, CLDN3, NUP54, NLGN1, JUP, P2RX1]
GO:0045840;positive regulation of mitotic nuclear division;8.0;0.7140352122741334;0.7320176061370667;9.138976027173417;276.06341799230654;5.75172193694532;0.009239594159256459;0.6691433273378073;[TGFA, NUP62, SH2B1, RANBP1, TGFB1, EGF, BTC, CD28]
GO:0045603;positive regulation of endothelial cell differentiation;7.0;0.8436909121759173;0.7727648213451592;9.503361109538115;205.17606198895368;7.004484905440688;0.006867058148302753;0.7091290490632969;[TMEM100, CDH5]
GO:0051290;protein heterotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;6.444869117505266;0.002859955186148837;0.6805102716434839;[NLGN1, NUP54]
GO:0043305;negative regulation of mast cell degranulation;11.0;0.9326813400603323;0.8987696223598284;9.607470843294289;1077.1478631716955;7.9853141584524145;0.03605116961021663;0.8407982897480031;[IL13RA2]
GO:0042699;follicle-stimulating hormone signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;62.84085921303097;8.16763571524637;0.002103227004758593;0.7408135829017477;[LHCGR]
GO:0045964;positive regulation of dopamine metabolic process;8.0;0.9326813400603323;0.8413406700301662;9.574457031221845;287.85429884722043;7.9853141584524145;0.009634224330366589;0.7833693374183408;[GPR37]
GO:0001992;regulation of systemic arterial blood pressure by vasopressin;7.0;1.0;0.8509193652572005;9.628524252492122;25.380868944193306;8.16763571524637;8.494748422630829E-4;0.7686126355688037;[AVPR1A]
GO:0051048;negative regulation of secretion;6.0;0.5318528234273745;0.5890467243038318;7.102795608183866;46.36667726786087;4.478756261132433;0.001551850960854928;0.552164116067923;[IL13RA2, GHSR, IL1R2, F2R, NLRP3, DRD4, CYP4F2, INHBA, IFNA2, CCR2, CEACAM1, BANK1, TLR8, GNAI2, CNR1, EGF, LILRB1, NLRP12, FCGR2B, LGR4]
GO:0051289;protein homotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;5.433268205826786;0.002859955186148837;0.6287769539759931;[CDA, ACPP, FBP1, HM13, SAMHD1, CD79A]
GO:1905233;response to codeine;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;91.95678064542024;9.777073627680469;0.0030777106924725914;0.8509193652572005;[ABCB4]
GO:0043318;negative regulation of cytotoxic T cell degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;1135.3772244618756;9.083926447120524;0.03800005392957609;0.8969813732811862;[CEACAM1, FCGR2B]
GO:1905232;cellular response to L-glutamate;7.0;1.0;0.8509193652572005;9.628524252492122;543.0623632319648;8.390779266560578;0.01817580857297763;0.7800242071602487;[ABCB4]
GO:1904385;cellular response to angiotensin;8.0;1.0;0.875;9.628524252492122;462.69925393661634;7.379178354882098;0.015486127626965131;0.7523715242355574;[CDC6, SLC30A10]
GO:1905231;cellular response to borneol;6.0;1.0;0.8231203125901445;9.628524252492122;82.1226699471212;9.777073627680469;0.0027485718575255523;0.8231203125901445;[ABCB4]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[EDNRB, GPR171, C3AR1, AKT1, PROK2, TAS2R10, TAS2R13, TAAR2, TRHR, ADCY9, AGTR1, FPR1, FPR3, FPR2, CCR10, CCR1, ABCA1, GPR15, FZD5, OR2J2, AZU1, NMBR, MARCO, PNOC, GPR18, GPR19, GPR25, GABRB1, CD3E, CCR9, FFAR2, CCR6, CCR2, GPR37, RHOG, GPBAR1, TACR3, AGTRAP, PTH2R, AVPR1A, SORCS3, MC3R, PTAFR, CXCR5, CXCR4, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, GABRE, GPR157, P2RY13, GABBR1, SORT1, GABRA5, P2RY14, GPR6, RAMP1, LGR4, F2RL3, CHRM2, CHRM1, CELSR1, CXCL16, RGS1, CCRL2, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, SUCNR1, CALCRL, GPR87, C5AR1, GPR85, GPR84, HRH4, DRD4, HTR1E, CAV1, GPR98, GNB2, TAS2R7, OR1G1, CXCL1, CXCL2, GRM5, PTGIR, GLP2R, LRP1, OR1E1, P2RY6, CNR1, P2RY2, OR2W1, S1PR3, OR12D3, TSHR, OR11A1]
GO:1905237;response to cyclosporin A;6.0;0.9326813400603323;0.7894609826203107;9.533214072687796;72.72722829191152;9.777073627680469;0.002434114880674206;0.8231203125901445;[ABCB4]
GO:0030183;B cell differentiation;6.0;0.7307253602413294;0.6884829927108091;9.022388448921806;64.35544597283358;5.2552850506314295;0.0021539188605695985;0.5918758344751833;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, HHEX, BLNK, TPD52, CR2, IFNA14, IFNA16, NFAM1, MSH2, IFNA10, CD79B, CD79A, IFNA21, BCL6, FCGR2B, ITM2A]
GO:0031394;positive regulation of prostaglandin biosynthetic process;10.0;0.9326813400603323;0.8815816818910864;9.59462270081644;954.1434290848206;8.390779266560578;0.03193432189813256;0.8443458537639685;[AVPR1A, PTGS2]
GO:0030182;neuron differentiation;4.0;0.5833093054345528;0.5416546527172764;7.212610474191073;21.066225782797595;4.296434704338478;7.050676185779127E-4;0.4697198705845162;[MEF2C, RUNX2, JAG1, BCL11B, FZD5, INHBA, USH2A, NR4A2, ITM2C]
GO:1905235;response to quercetin;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;83.8240692754011;9.777073627680469;0.0028055161618830964;0.7902410118609202;[ABCB4]
GO:0061088;regulation of sequestering of zinc ion;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;37.41913998203334;7.474488534686424;0.001252384940159041;0.7053660038532718;[SLC30A10]
GO:0042220;response to cocaine;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;106.24722930474235;6.343086423195323;0.0035559991485312878;0.647506047256038;[CNR1, TACR3, DNM2]
GO:0042100;B cell proliferation;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;50.60132884827668;6.166155715036245;0.00169358093831245;0.6384578026126634;[IFNA5, IFNA4, IFNA7, MEF2C, CR2, IFNA14, IFNA16, IFNA2, CD180, IFNA8, CD79A, MS4A1, IFNA21, IFNA10]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, SLC11A1, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, LILRB2, LILRB3, QPCT, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0007188;adenylate cyclase-modulating G-protein coupled receptor signaling pathway;7.0;0.7090535922965819;0.7054461614054914;8.712233520617966;27.67007993335845;4.535326612620827;9.260926739143067E-4;0.5828561791408859;[CHRM2, CHRM1, GRM5, RGS1, LHCGR, PTGIR, GPR37, GLP2R, NPY1R, MC3R, ADCY9, CALCRL, FPR1, FPR2, GPR84, GNAI1, GNAI2, CNR1, HRH4, FLNA, S1PR3, DRD4, ABCA1, GABBR1, HTR1E, TSHR, MARCO, RAMP1, LGR4]
GO:0007189;adenylate cyclase-activating G-protein coupled receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.249034630787218;56.871035456649615;5.192106149009898;0.0019034223761250782;0.6617651750982834;[CALCRL, GNAI2, ABCA1, LHCGR, PTGIR, TSHR, MC3R, ADCY9, RAMP1, LGR4]
GO:0042102;positive regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;564.8543510249671;5.212725436212633;0.018905166792893686;0.6628196464047262;[TFRC, CD3E, PYCARD, IL6R, ICOSLG, CCR2, HLA-DPA1, PDCD1LG2, CD274, BLM, HHLA2, CORO1A, LILRB2, CD4, CD28, HLA-DPB1, CD24]
GO:0042104;positive regulation of activated T cell proliferation;10.0;1.0;0.9152410118609203;9.628524252492122;649.8896198547563;6.599019797332524;0.021751220713853325;0.7527151911823093;[HHLA2, PYCARD, CD24, IL6R, ICOSLG]
GO:0001755;neural crest cell migration;6.0;0.7980440201809971;0.722142322680643;9.089527751759436;22.57397290845719;5.825829909099042;7.555305579894227E-4;0.6210535250702663;[NRP1, SEMA4B, EDNRB]
GO:0002605;negative regulation of dendritic cell antigen processing and presentation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;55.710237364246;9.083926447120524;0.0018645715086227877;0.7876727335416686;[FCGR2B]
GO:0014826;vein smooth muscle contraction;10.0;1.0;0.9152410118609203;9.628524252492122;72.04955416761116;8.390779266560578;0.002411433737600989;0.8443458537639685;[EDNRB]
GO:0061092;positive regulation of phospholipid translocation;9.0;1.0;0.896240625180289;9.628524252492122;348.31453857334856;8.67846133901236;0.011657774143316984;0.8400575416471059;[ABCB4]
GO:0032597;B cell receptor transport into membrane raft;11.0;0.9326813400603323;0.8987696223598284;9.59462270081644;336.41565742558566;9.777073627680469;0.011259529299599152;0.9324289523296623;[CD24]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, GHSR, DUSP1, TACR3, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0010107;potassium ion import;10.0;0.9326813400603323;0.8815816818910864;9.571365838652174;121.72212082045542;6.063501560976162;0.004073929841064025;0.7253287636709003;[SLC12A1, KCNJ15, KCNJ16, ATP1B2, ATP1B1]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CTGF, CXCL16, FGF5, VSTM1, MEF2C, IFNA14, IFNA16, BTC, IFNA10, TGFA, PDGFC, IFNA21, TGFB1, JAG1, TNFSF12, INHBA, GH1, PNOC, OGN, IFNA5, IFNA4, NRP1, IFNA7, IFNA2, CXCL1, PRL, IFNA8, CXCL2, HBEGF, NLGN1, CLEC12B, RETN, GPNMB, EGF, CMTM2, FCGR2B]
GO:0086053;AV node cell to bundle of His cell communication by electrical coupling;5.0;1.0;0.7902410118609202;9.628524252492122;36.28951994211526;9.083926447120524;0.001214577574015016;0.7547934328124444;[GJC1]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[SCARB2, TFRC, ANPEP, CLEC5A, ITGB6, CR2, CR1, CXADR, GYPA, GPR15]
GO:1904155;DN2 thymocyte differentiation;8.0;1.0;0.875;9.628524252492122;68.09311559111913;9.777073627680469;0.0022790152990093482;0.875;[CCR6]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CYFIP1, PLXND1, VRK1, CORO1A, PTK2, RHOG, ARAP3, RHOU, FGD4, PDPN]
GO:0007271;synaptic transmission, cholinergic;8.0;1.0;0.875;9.628524252492122;25.73829654599903;6.409777797693995;8.61437622431563E-4;0.7027963346592216;[CHRM2, SLC5A7, CHRNB4, CHRM1]
GO:0007274;neuromuscular synaptic transmission;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;25.73829654599903;6.250713103064308;8.61437622431563E-4;0.6946617587785947;[SLC5A7, CHRNB4, EGR3, CHRM1]
GO:0032230;positive regulation of synaptic transmission, GABAergic;8.0;1.0;0.875;9.628524252492122;135.4246808583232;7.212124270218933;0.0045325421940280546;0.7438283705770736;[NLGN1]
GO:1904156;DN3 thymocyte differentiation;8.0;1.0;0.875;9.628524252492122;68.09311559111913;9.777073627680469;0.0022790152990093482;0.875;[CCR6]
GO:0045861;negative regulation of proteolysis;8.0;0.612588685250814;0.681294342625407;8.712233520617966;337.1756827485802;3.92774884773361;0.011284966663181396;0.5758652587320976;[SPINT2, AKT1, IL1R2, POR, SPINT1, SLPI, SFN, SERPINB10, PTGS2, TM4SF20, NR1H2, TNFRSF10C, CRIM1, TNFRSF10B, DHCR24, LRRK2, CR1, TNFRSF1B, MMP9, LTF, NLRC4]
GO:0045741;positive regulation of epidermal growth factor-activated receptor activity;12.0;0.9326813400603323;0.9144609826203107;9.611429819132821;2972.107935112762;7.292166977892469;0.09947377786474029;0.8210420709600095;[EGF, TGFA]
GO:0045746;negative regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;188.1075192762445;6.193554689224359;0.006295789384399518;0.6676580400938822;[EGF, BCL6]
GO:0099566;regulation of postsynaptic cytosolic calcium ion concentration;11.0;0.8933024483968273;0.8790801765280758;9.57973408832269;290.3013502407617;8.67846133901236;0.00971612493830514;0.8762458687964789;[GRM5]
GO:0001964;startle response;5.0;1.0;0.7902410118609202;9.628524252492122;22.2265316404705;7.212124270218933;7.439020114267487E-4;0.659069382437994;[SLITRK6, KCNH1]
GO:0034765;regulation of ion transmembrane transport;6.0;0.45556283921517005;0.5509017321977295;6.676594601596523;33.03735142972539;3.697140432584879;0.0011057304206669666;0.512192246247148;[, KCNG2, SLC8A1, AKT1, SCN1A, KCNH1, MEF2C, F2R, CACNA2D3, ACTN4, ATP1B2, ATP1B1, GEM, KCNQ1, KCNE3, KCNE4, HVCN1, CORO1A, CD19, SCN3A, DRD4, LYN, TGFB1, CAV1, FXYD6, KCNK5, CTSS, GRM5, KCND2, TRPC1, MMP9, DNM2, TMEM37, NLGN1, PTAFR, FLNA, KCNJ15, KCNJ16, TSPAN13, F2RL3]
GO:0034644;cellular response to UV;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;66.19362175939281;5.420364800990877;0.0022154409498949313;0.628117073252615;[CDKN1A, PTPRK, CHEK1, MME, PCNA, PTGS2, POLD1]
GO:0033674;positive regulation of kinase activity;9.0;0.6073376606709605;0.6999094555157693;8.620883742029738;265.89784403492143;3.4106031799490317;0.008899361547325376;0.5706590304121504;[, CCNH, TCL1A, AKT1, PROK2, ACSL1, SLC11A1, EPHA3, FPR1, TGFA, FPR2, IQGAP3, PRKAR2B, PDGFC, ELANE, LYN, EGR1, ACE, FZD5, CDC6, AZU1, PTK2, NOX4, CD24, EZH2, CDKN1A, MAP4K1, DUSP6, TLR4, CXCR4, PKN1, IL6R, MAP2K2, F2R, ADAM9, C5AR1, TNFRSF11A, STAP1, DRD4, TGFB1, TNFRSF10B, GH1, CSPG4, LAT, LRRK2, GHR, GRM5, PSRC1, CHI3L1, LTF, EGF, CD4, TEK]
GO:0014911;positive regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;201.77833622021802;6.280566066213989;0.0067533393245778365;0.6961884407023742;[DOCK5, NRP1, P2RY6, NOX4]
GO:1902093;positive regulation of flagellated sperm motility;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;154.66121258067747;7.474488534686424;0.005176371599020676;0.7331650565203278;[TACR3, CCR6]
GO:0086021;SA node cell to atrial cardiac muscle cell communication by electrical coupling;5.0;1.0;0.7902410118609202;9.628524252492122;36.28951994211526;9.083926447120524;0.001214577574015016;0.7547934328124444;[GJC1]
GO:0032228;regulation of synaptic transmission, GABAergic;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;30.61939422688933;6.311337724880743;0.001024803569108247;0.6736814700148209;[NLGN1, CNR1]
GO:0032467;positive regulation of cytokinesis;7.0;0.7043150770688792;0.7030769037916401;9.015419779605713;142.0565341908292;6.193554689224359;0.004754504356786525;0.6676580400938822;[SVIL, CXCR5, TAS2R13, CDC6, CIT, RACGAP1, NUP62]
GO:0006071;glycerol metabolic process;7.0;0.7866048967936545;0.7442218136540277;9.303101852057495;71.14030572701571;6.832634648514029;0.0023810020105647298;0.7003406189322132;[DGAT2, MOGAT2]
GO:0045759;negative regulation of action potential;5.0;0.7586651285174919;0.6695735761196662;9.089527751759436;33.79526974805598;7.8311634786251565;0.0011310972646992894;0.6907270763441554;[KCNE3, CNR1]
GO:0007043;cell-cell junction assembly;5.0;0.7508913569872202;0.6656866903545304;8.817594036275793;53.94372379865016;5.16195311083921;0.0018054478893412883;0.554223534004606;[GJC1, CDH5, CDH3, CDH1, JUP, LSR, ACTN4, GJB2, CLDN3, CD9, TLN1]
GO:0006196;AMP catabolic process;11.0;1.0;0.9324289523296623;9.628524252492122;7868.309748082107;9.083926447120524;0.2633452462492735;0.8969813732811862;[NT5E]
GO:0007286;spermatid development;5.0;1.0;0.7902410118609202;9.628524252492122;72.7828096339012;5.370354380416217;0.0024359751381706407;0.5648811846224242;[JAM3]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[LRP1, TREM2, AKT1, RHOG, EPHA3]
GO:0007162;negative regulation of cell adhesion;5.0;0.5651597194614189;0.5728208715916296;7.400047131651798;38.26822196421712;4.255612709818223;0.001280802949978559;0.5078732437472537;[, PLXND1, SPINT2, LGALS3, CDH1, TNR, LAG3, ACTN4, CLDN7, CD274, TACSTD2, TGFB1, JAG1, PTK2, BCL6, IFNA2, ARHGAP6, ARG1, PAWR, PDCD1LG2, CEACAM1, GPNMB, EPCAM, JAM2, LILRB1, LILRB2, CD9, FCGR2B, SIPA1]
GO:0007169;transmembrane receptor protein tyrosine kinase signaling pathway;7.0;0.579397892394798;0.6406183114545996;7.564831067780425;28.111912685638995;3.5644675319289507;9.408804185094754E-4;0.533206400604739;[CYFIP1, SLA2, STMN1, AKT1, BTC, BTK, EPHA3, SDC2, TGFA, SLC30A10, FLRT2, PDGFC, LYN, PTK2, NRP1, PTPRR, NRP2, CD3E, GAB1, HBEGF, SORT1, SULF2, NCF4, CTGF, FGF5, GRAP2, AP2M1, TSC2, KIF16B, BLK, RASGRP4, FOXO1, STAP1, TGFB1, CRIM1, BMX, GH1, CSPG4, GHR, BLNK, MMP9, REPS2, TRAT1, EGF, CD4, CD7, TEK]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, SLA2, C3AR1, AKT1, MEF2C, HHLA2, FPR1, FPR3, FPR2, SLC30A10, PDGFC, LYN, ABCA1, JAG1, HLA-DRB4, VANGL1, SIGLEC9, LRRC4, HLA-DPA1, PTH2R, LRRC19, PTAFR, PTGS2, FLNA, P2RY13, P2RY14, HLA-DPB1, LGR4, NCF4, F13A1, CTGF, AP2M1, LAG3, IFNA14, IFNA16, IFNA10, BLK, CD274, GPR87, TACSTD2, LY96, TNFRSF11A, CORO1A, FOXO1, TNFRSF17, IFNA21, GPR98, TNFRSF10C, TNFRSF10B, BMX, LCN2, HLA-DRA, CIITA, ITGAM, ITGB4, LRRK2, HHEX, FCGR3A, ITGB6, TNFRSF1B, TSPAN33, FCGR1B, TSPAN13, FCGR2A, FCGR2B, ICAM2, BTC, BTK, EPHA3, SDC2, TGFA, CD19, TSPAN5, TSPAN2, CCR1, EGR1, TNFSF12, PTK2, CD28, SDC1, CD24, IGHM, NRP1, PTPRR, NRP2, TNFRSF13B, CD3G, PTPRK, CD3E, CCR9, FCER1A, CD37, CCR6, MUC15, CD36, CCR2, GAB1, LAT2, IGHD, GNAI2, IGKC, SORT1, CELSR1, CCRL2, IL6R, GEM, OSCAR, CCNE1, PSEN2, RASGRP4, CRIM1, INHBA, GH1, IGKV3-20, SIRPB1, GHR, GRM5, NUP62, MMP9, SAMHD1, EGF, CD2, CD4, CD7, CD9, TEK, CDA, CYFIP1, STMN1, GPR171, FLRT2, IGHA1, HLA-DQA1, FZD5, CDK14, DENND1B, CDKN1A, ASGR2, NFAM1, AES, FCER2, HBEGF, ENG, HLA-DQB1, ALOX5, GPR157, G0S2, SULF2, ZYX, PLP1, CSF3R, PLXND1, IL5RA, FGF5, PYCARD, CDH5, IGHG1, CDH3, FCGRT, GRAP2, IL13RA2, TLE4, CLEC4D, ADAM9, CD151, CALCRL, IGLV1-44, BCL6, CSPG4, LAT, CR2, CR1, P2RY6, P2RY2, SEMA4B, P2RX5, P2RX1, EDNRB, ICOSLG, ACSL1, IL1R1, IL1R2, RUNX2, TLN1, PFN1, APCDD1, CD79B, CD79A, CCR10, NMBR, MARCO, IFNA5, ROBO2, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, GP1BB, GPBAR1, PDCD1LG2, IL17RB, CEACAM1, RHOU, TLR4, TLR2, CXCR5, CXCR4, CXCR1, CXCR2, LILRB1, LILRB2, LILRB3, KRT19, IL18RAP, TSC2, KIF16B, PRTN3, C5AR1, CSF2RB, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, TMEM100, LRRTM4, BLNK, DCC, GLP2R, CLEC12B, REPS2, S1PR3, TRAT1, TSHR, LTBR]
GO:0043215;daunorubicin transport;7.0;1.0;0.8509193652572005;9.628524252492122;103.949567617783;9.777073627680469;0.0034790984796300266;0.8509193652572005;[ABCB4]
GO:0097155;fasciculation of sensory neuron axon;8.0;1.0;0.875;9.628524252492122;32.20751195316447;8.67846133901236;0.0010779564401935146;0.8188169164668168;[EPHA3]
GO:0097156;fasciculation of motor neuron axon;8.0;1.0;0.875;9.628524252492122;32.20751195316447;9.083926447120524;0.0010779564401935146;0.839552420951524;[EPHA3]
GO:0035725;sodium ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;113.92400819162063;5.014899692882714;0.0038129340292226534;0.6314622035107071;[SLC24A1, SLC24A4, SLC8A1, SCN3A, SCN1A, SLC13A1, SLC6A16, SLC6A15, SLC12A1, ATP1B2, ATP1B1, SLC6A6]
GO:0090179;planar cell polarity pathway involved in neural tube closure;10.0;1.0;0.9152410118609203;9.628524252492122;275.5135961891709;7.212124270218933;0.009221192118313007;0.7840693824379941;[CELSR1]
GO:0007098;centrosome cycle;4.0;1.0;0.75;9.628524252492122;37.692070457630365;6.088194173566533;0.0012615196775557923;0.5613505331661754;[HEPACAM2, NUP62]
GO:0060405;regulation of penile erection;4.0;0.8933024483968273;0.6966512241984136;9.34084218004034;34.931128415581114;7.8311634786251565;0.0011691134320949222;0.6504860644832351;[EDNRB, CNR1]
GO:0060406;positive regulation of penile erection;5.0;1.0;0.7902410118609202;9.628524252492122;118.0711512965144;8.16763571524637;0.003951735176756968;0.7079342821725234;[EDNRB]
GO:1902950;regulation of dendritic spine maintenance;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;39.538107659814585;7.474488534686424;0.0013233048813872785;0.7331650565203278;[FCGR2B]
GO:0048754;branching morphogenesis of an epithelial tube;6.0;0.7436939687323844;0.6949672969563367;8.8813098506619;51.7127811195946;4.956792062075433;0.0017307802455913577;0.5766108891590862;[NRP1, PLXND1, HHEX, ENG, TGFB1, EGF, PPP1CA]
GO:0022010;central nervous system myelination;5.0;1.0;0.7902410118609202;9.628524252492122;21.182224696661116;7.379178354882098;7.0894999783268E-4;0.6676125360964777;[PLP1]
GO:0001545;primary ovarian follicle growth;3.0;0.8933024483968273;0.6447715367885581;9.292052015870908;21.717098748465986;8.67846133901236;7.268517509911946E-4;0.6419372290569613;[LHCGR]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, EGR1, TGFB1, CAV1, NR4A2, NOX4, CD24, KCND2, AGTRAP, TLR2, CXCR4, PTGS2, TEK]
GO:0002755;MyD88-dependent toll-like receptor signaling pathway;12.0;0.8933024483968273;0.8947715367885583;9.5544162803384;412.6549923027037;6.280566066213989;0.013811191226989502;0.7693087532925187;[LY96, CD36, TLR1, BTK, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2]
GO:0071773;cellular response to BMP stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.280566066213989;0.003262744749111514;0.6443087532925187;[TMEM100, SPINT1, SPINT2, RUNX2]
GO:0002638;negative regulation of immunoglobulin production;7.0;0.7980440201809971;0.7499413753476991;9.193206181234276;77.13462423321295;7.474488534686424;0.0025816264564307383;0.7331650565203278;[BCL6, FCRL3, FCGR2B, IL13RA2]
GO:2000510;positive regulation of dendritic cell chemotaxis;10.0;0.9326813400603323;0.8815816818910864;9.593432932680852;509.141903474748;7.697632086000634;0.01704052131133542;0.8088982747154926;[CCR6]
GO:0015824;proline transport;10.0;0.8436909121759173;0.837086467948879;9.55953138100517;85.82177420350179;7.57984905034425;0.0028723775480089153;0.8028748447945538;[SLC36A1, SLC6A15]
GO:0015701;bicarbonate transport;7.0;1.0;0.8509193652572005;9.628524252492122;31.887457555831563;6.015873511986907;0.0010672445075450394;0.6585714164269392;[SLC4A7, CA4, SLC26A8, SLC26A7, SLC26A3]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2C, AGTR1, FPR1, FPR2, IQGAP3, PRKAR2B, SFN, LYN, ABCA1, AZU1, ARHGAP6, DUSP1, DUSP6, PTAFR, PKN1, LGR4, CTGF, KCNH1, MSH6, MSH2, BLK, LY96, TNFRSF10B, BMX, CORO2A, LRRK2, TNFRSF1B, E2F7, SH2B1, BTC, BTK, RACGAP1, CCR1, PTK2, RGL4, CD24, RGL1, BRCA2, CCR9, CCR6, CD36, SPTAN1, CCR2, LAT2, MC3R, PCNA, GNAI2, RAMP1, CELSR1, CCRL2, DOK3, PSEN2, RASGRP4, GH1, GHR, GRM5, EPS8L1, EGF, TEK, CYFIP1, STMN1, ADCY9, LGALS12, PLK2, CDKN1A, NFAM1, CIT, HBEGF, GSN, IL5RA, SLC8A1, FGF5, PYCARD, GRAP2, STK32B, LHCGR, MAP2K2, DGKZ, NRBP1, RAB32, MELK, CALCRL, DHCR24, BCL6, CNOT3, CSPG4, LAT, TREM1, EDNRB, PPP2R1A, CHEK1, SIK1, CCR10, PRL, RALGPS2, MAP4K1, RHOG, AVPR1A, TLR8, TLR7, RHOU, SGK1, TLR4, CXCR5, CXCR4, CXCR1, CXCR2, PDPN, MLH1, CAMK4, SIPA1, TSC2, ATP1B1, CSF2RB, TGFB1, SELE, DOCK5, MCTP1, CXCL1, TMEM100, BLNK, PTGIR, TSHR]
GO:0015820;leucine transport;10.0;0.8933024483968273;0.861892236059334;9.56398573135455;154.55075425776707;8.67846133901236;0.005172674658358902;0.8590579283277371;[SLC6A15]
GO:0035315;hair cell differentiation;6.0;0.811012628672052;0.7286266269261705;9.143016436710422;49.42682886488536;7.292166977892469;0.0016542714808497024;0.6960420709600095;[JAG1, USH2A]
GO:0050710;negative regulation of cytokine secretion;9.0;0.6954798709641801;0.743980560662379;9.089527751759436;549.9868642983072;5.734022359845919;0.01840756539202174;0.6894787953221185;[IFNA2, NLRP3, GHSR, IL1R2, LILRB1, NLRP12, BANK1, TLR8, FCGR2B, LGR4]
GO:0055064;chloride ion homeostasis;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;35.39315814371355;7.212124270218933;0.0011845771512957555;0.7438283705770736;[SLC12A1]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[TNFAIP6, CDH5, GHSR, IL1R2, TNFRSF1B, CALCRL, NT5E, NLRP3, ELANE, NLRP12, TEK, FCGR2B]
GO:0034220;ion transmembrane transport;5.0;0.44800904580126355;0.514245534761552;6.183841758890227;26.332710660334534;2.96803432163749;8.813321279004005E-4;0.4420264250971726;[AQP9, SCN1A, SLC6A16, SLC11A1, SLC6A15, CACNA2D3, CLDN4, KCNQ1, SLC22A4, SLC30A10, GJC1, KCNMB3, KCNN3, SCN3A, ABCA1, SLC6A6, FXYD6, GABRB1, SLC7A11, KCND2, TMEM37, SLC7A7, SLC7A8, CLDN17, SGK1, ANO10, SLC17A6, GABRE, GABRA5, KCNG2, STEAP4, DENND5B, SLC8A1, SLC16A3, KCNH1, CHRNB4, F2R, ATP1B2, ATP1B1, KCNE3, KCNE4, HVCN1, SLC41A2, SLC1A3, SLC38A11, SLC38A6, CLCA4, SLC26A8, SLC26A7, SLC26A3, KCNK5, ATP2A3, SLC40A1, SLC36A1, TRPC7, SLC13A1, TRPC1, SLC24A1, SLC24A4, SLC12A1, KCNJ15, KCNJ16, SLC4A7, P2RX5, P2RX1]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[FFAR2, CCR2, IL17RB, BTK, AGTR1, TLR10, TLR7, TLR4, S100A8, TLR2, SUCNR1, TNFRSF11A, PTGS2, PLA2G7, CNR1, NLRP12, CD28]
GO:0060999;positive regulation of dendritic spine development;11.0;0.9326813400603323;0.8987696223598284;9.596775554177542;671.848150157114;6.113511981550823;0.022486152961678982;0.7450742393735527;[NLGN1]
GO:0002523;leukocyte migration involved in inflammatory response;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;29.137022145890857;7.379178354882098;9.751899096054872E-4;0.7004918368257019;[FFAR2, CCR6, SELE, ELANE, S100A8, JAM3]
GO:2000404;regulation of T cell migration;9.0;0.6954798709641801;0.743980560662379;9.168991923113682;54.41624510224751;6.250713103064308;0.0018212627521311273;0.7159023839588838;[PYCARD, CCR6, CCR2]
GO:0001558;regulation of cell growth;5.0;0.5833093054345528;0.5818956645781967;7.6590836060266145;26.25041167864861;3.793137346993279;8.785776550476476E-4;0.4842222321850823;[CDA, CYFIP1, CPNE5, PPP2R1A, AKT1, AGTR1, SFN, NRP1, CDKN1A, AVPR1A, IL17RB, CEACAM1, SGK1, HBEGF, CDKN2C, SIPA1, CTGF, CXCL16, TNR, S100A8, IGFBP7, TGFB1, SYT2, CRIM1, INHBA, BCL6, DCC, DNM2, PSRC1, FBP1, SEMA4B]
GO:0002768;immune response-regulating cell surface receptor signaling pathway;6.0;0.6835726970475526;0.6649066611139208;8.807543700422292;76.39633531366081;3.743987405881668;0.0025569165907102184;0.5145880026401528;[, CYFIP1, ICAM2, SLA2, C3AR1, ICOSLG, MEF2C, BTK, HHLA2, FPR1, FPR3, FPR2, CD79B, CD79A, CD19, IGHA1, HLA-DQA1, LYN, HLA-DRB4, PTK2, CD28, CD24, IGHM, DENND1B, CD3G, CD3E, FCER1A, FFAR2, MUC15, HLA-DPA1, LAT2, IGHD, HLA-DQB1, IGKC, LILRB1, LILRB2, HLA-DPB1, IGHG1, FCGRT, GRAP2, CLEC4D, BLK, C5AR1, IGLV1-44, BMX, HLA-DRA, IGKV3-20, LAT, FCGR3A, CR2, CR1, CLEC12B, FCGR1B, TRAT1, CD4, FCGR2A, FCGR2B]
GO:2000768;positive regulation of nephron tubule epithelial cell differentiation;8.0;1.0;0.875;9.628524252492122;415.05780765516636;8.67846133901236;0.013891611294443005;0.8188169164668168;[CD24]
GO:0002407;dendritic cell chemotaxis;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;93.27947089202779;6.8867018697843045;0.0031219799446826077;0.7031056191423581;[CCR1, CXCR1, CXCR2, CXCR4, CCR6, CCR2]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[EDNRB, C3AR1, IL1R1, IL1R2, BTK, AGTR1, PLA2G7, CD19, ELANE, LYN, BST1, CD28, FFAR2, CCR2, IL17RB, TLR10, TLR7, TLR4, TLR2, PTGS2, NT5E, IGKC, NLRP12, ZYX, CDH5, IGHG1, GHSR, S100A8, SUCNR1, CALCRL, C5AR1, TNFRSF11A, IGLV1-44, NLRP3, SELE, BCL6, IGKV3-20, TNFAIP6, CR2, CR1, TNFRSF1B, CNR1, TEK, FCGR2B]
GO:0050848;regulation of calcium-mediated signaling;7.0;0.6664901433067099;0.6841644369105555;8.734706376470026;45.070113835906206;5.266214121163619;0.001508456149618737;0.6202338003175094;[LRRK2, TREM2, SLA2, CD3E, TMEM100, TRAT1, BST1, P2RX5, CD4]
GO:0033004;negative regulation of mast cell activation;7.0;0.8653626801206646;0.7836007053175329;9.5544162803384;126.92306413003195;7.379178354882098;0.00424800073309046;0.728290889492758;[CNR1, IL13RA2]
GO:0050966;detection of mechanical stimulus involved in sensory perception of pain;6.0;1.0;0.8231203125901445;9.628524252492122;71.50580126066325;7.379178354882098;0.0023932348171512878;0.7004918368257019;[SCN1A]
GO:0051932;synaptic transmission, GABAergic;8.0;1.0;0.875;9.628524252492122;25.73829654599903;7.138016298065211;8.61437622431563E-4;0.7400384854347593;[GABRA5, GABRE]
GO:0098904;regulation of AV node cell action potential;8.0;0.8259837884571596;0.7879918942285797;9.503361109538115;70.34216499897342;8.67846133901236;0.0023542889586771745;0.8188169164668168;[CXADR]
GO:0071526;semaphorin-plexin signaling pathway;6.0;0.811012628672052;0.7286266269261705;9.089527751759436;26.50247477320489;6.166155715036245;8.87013979980389E-4;0.6384578026126634;[NRP1, NRP2, PLXND1, SEMA4B, FLNA]
GO:0007193;adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.117698628726131;28.36322711391944;5.334422371190153;9.492916862557204E-4;0.6478026081386739;[CHRM2, GABBR1, CHRM1, GPR37, HTR1E, NPY1R, FPR2, GNAI1, GNAI2, MARCO, GRM5, ADCY9, RGS1, HRH4, FLNA, S1PR3, DRD4]
GO:0032270;positive regulation of cellular protein metabolic process;7.0;0.47017759384120705;0.586008162177804;7.412950536487706;288.49227156764;2.455885070940991;0.00965557670318086;0.47651344199545814;[, AKT1, AGTR1, FPR1, FPR2, SLC30A10, IQGAP3, PRKAR2B, PDGFC, LYN, AZU1, NOX4, EZH2, GPR37, DUSP6, PTAFR, PTGS2, PKN1, CTGF, IFNA14, IFNA16, S100A8, IFNA10, TNFRSF11A, IFNA21, TNFRSF10B, LRRK2, TNFRSF1B, LRP1, FCGR2B, CCNH, TCL1A, EPHA3, TGFA, CCR1, EGR1, PTK2, CD28, CD24, NRP1, CD3E, CD36, BANK1, GNAI2, NLRP12, RAMP1, IL6R, CAV1, INHBA, GH1, GHR, GRM5, MMP9, PSRC1, CHI3L1, EGF, CD4, TEK, MYB, PROK2, ELANE, NDFIP2, ACE, FZD5, PLK2, CDC6, CDKN1A, FCRL3, HBEGF, ENG, GPNMB, GSN, NR1H2, PYCARD, MAP2K2, F2R, ADAM9, DRD4, OSBPL7, WFS1, BCL6, CSPG4, CCDC22, LAT, TREM2, CR1, NLRC4, P2RX1, EDNRB, SKP2, ACSL1, SLC11A1, MARCO, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, MAP4K1, TLR4, CXCR4, LILRB2, C5AR1, STAP1, NLRP3, TGFB1, LTF, LTBR]
GO:0007194;negative regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6285.124034700197;6.481236761676141;0.21035744519701882;0.7795710619905949;[P2RY13, GABBR1, EDNRB, GPR87, HRH4, GNAI2, CCR2]
GO:0007197;adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.5544162803384;81.68848396009673;7.8311634786251565;0.0027340400432818626;0.7967266896635242;[CHRM2, CHRM1, HRH4]
GO:0055075;potassium ion homeostasis;8.0;0.8933024483968273;0.8216512241984136;9.533214072687796;71.74727346628734;6.409777797693995;0.0024013166745626502;0.7027963346592216;[SLC12A1, ATP1B2, ATP1B1]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, FZD5, CDC6, NOX4, CDKN1A, TNFRSF13B, PRL, PTPRK, BRCA2, CD33, DUSP1, ARG1, PAWR, PDCD1LG2, CEACAM1, TLR2, PTGS2, GPNMB, PDPN, CDKN2C, LILRB1, LILRB2, PKN1, CDH5, DACH1, F2R, TSC2, HGS, CD274, NACC2, IGFBP7, TGFB1, CAV1, HMGA1, DHCR24, INHBA, BCL6, OGN, CXCL1, NUP62, PTGIR, E2F7, CD9, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, AKT1, PROK2, MEF2C, CLDN7, AGTR1, ATF3, HHLA2, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, HLA-DPA1, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, LRG1, HLA-DPB1, CHRM1, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, BCL6, KLF5, TCL1A, EDNRB, SKP2, ICOSLG, RUNX2, BTC, TGFA, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, NRP1, NRP2, PRL, CD3E, CCR2, RHOG, PDCD1LG2, AVPR1A, CEACAM6, GNAI2, CXCR2, LILRB2, IL6R, GHSR, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, GLP2R, MMP9, LTF, S1PR3, EGF, MEIS2, TSHR, CD4, TEK]
GO:0007196;adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;85.0206884702681;7.57984905034425;0.002845565929447937;0.7838744581139225;[GRM5]
GO:0055078;sodium ion homeostasis;8.0;0.9326813400603323;0.8413406700301662;9.533214072687796;71.74727346628734;6.343086423195323;0.0024013166745626502;0.6993857346658935;[MC3R, CYP4F2, SLC12A1, ATP1B2, ATP1B1, SLC8A1]
GO:0060548;negative regulation of cell death;5.0;0.5408746917014966;0.5606783577116685;7.270369308343265;41.94029430001592;2.875336421023895;0.0014037039064071987;0.4372858501489002;[AKT1, PROK2, MEF2C, CLDN7, ABCB4, SLC30A10, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, GPR37, DUSP1, ANXA5, PTGS2, UNG, GPNMB, FLNA, GABRA5, CTGF, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, BCL6, LRRK2, TNFRSF1B, ADAMTS20, LRP1, NLRC4, SLC46A2, LGALS3, TCL1A, EDNRB, BTC, POR, EPHA3, EGR3, BCL11B, PTK2, VNN1, CD28, NRP1, CEACAM6, GNAI2, CXCR2, PDPN, LILRB1, GRINA, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF, TEK]
GO:0001890;placenta development;4.0;1.0;0.75;9.628524252492122;49.86610466882393;6.193554689224359;0.0016689736466849693;0.5667386748366816;[ABCB4, PTK2, E2F7]
GO:0050850;positive regulation of calcium-mediated signaling;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;239.92176968958296;6.039404009397101;0.008029965715936047;0.6838554019015759;[TREM2, CD3E, TRAT1, P2RX5, CD4]
GO:0070588;calcium ion transmembrane transport;9.0;0.7140352122741334;0.7532582313173557;9.078477915572849;116.6808485568922;4.562137870071484;0.003905202995253044;0.629548568016852;[DENND5B, ATP2A3, SLC8A1, TRPC7, TRPC1, F2R, CACNA2D3, TMEM37, SLC24A1, SLC24A4]
GO:0050859;negative regulation of B cell receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;309.61561130321576;7.9853141584524145;0.010362555874359037;0.7833693374183408;[FCRL3]
GO:0071312;cellular response to alkaloid;6.0;0.7866048967936545;0.7164227609869718;9.245532000236016;164.36700762083373;6.280566066213989;0.005501215824366272;0.6443087532925187;[BLM, ABCB4, SLC8A1, RAD51]
GO:0032269;negative regulation of cellular protein metabolic process;7.0;0.4739867211454891;0.587912725829945;7.449991808168055;289.3917989888356;2.854429736204582;0.009685683076446155;0.4968950347112605;[PID1, SPINT2, AKT1, SPINT1, ATF3, FLRT2, PRKAR2B, SFN, LYN, PKIG, CDKN1A, LRRC4, DUSP2, DUSP1, PAX5, DUSP6, ENG, SERPINB10, LRRC19, PTGS2, CDKN2C, NR1H2, PKN1, PYCARD, FOXO1, TNFRSF10C, TNFRSF10B, DHCR24, CNOT3, LRRK2, HHEX, CR1, TNFRSF1B, NLRC4, EDNRB, PPP2R1A, FBXO5, IL1R2, POR, SLPI, PTPRR, CEACAM1, BANK1, TLR4, GNAI2, TM4SF20, NLRP12, TSC2, TGFB1, CAV1, CRIM1, LRRTM4, NUP62, MMP9, LTF]
GO:0050852;T cell receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;219.43154282413207;4.981283082083729;0.007344176262756358;0.6699840603320352;[DENND1B, CD3G, CD3E, GRAP2, ICOSLG, HLA-DPA1, BTK, HLA-DQB1, HHLA2, HLA-DQA1, HLA-DRB4, TRAT1, BMX, CD4, CD28, HLA-DPB1, HLA-DRA, LAT]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[NRP1, IFNA2, TREM2, CD3E, GHR, GRM5, CD36, IL6R, BANK1, HBEGF, TGFA, STAP1, LYN, TGFB1, ACE, EGF, GH1, CD4, CSPG4, CD24]
GO:2000773;negative regulation of cellular senescence;7.0;1.0;0.8509193652572005;9.628524252492122;164.4250159730019;7.004484905440688;0.005503157311709213;0.7091290490632969;[BCL6, PLK2, SLC30A10]
GO:0050853;B cell receptor signaling pathway;10.0;0.9326813400603323;0.8815816818910864;9.582004236857228;219.43154282413207;4.948759890378168;0.007344176262756358;0.6683208227957298;[, BLK, IGHM, CD79B, CD79A, IGHG1, IGKC, CD19, IGHA1, LYN, MEF2C, BMX, LAT2, BTK, IGHD]
GO:0008292;acetylcholine biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;234.03382417514274;8.67846133901236;0.007832901478374668;0.7669372290569613;[SLC5A7]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD274, HHLA2, CD3E, GRAP2, BTLA, AKT1, ICOSLG, LYN, CAV1, PDCD1LG2, CD28, CD24]
GO:1901652;response to peptide;5.0;0.622025257344104;0.6012536405329723;8.140447197062288;43.799236587536825;3.924871147905995;0.0014659210318310812;0.4909591048900068;[CYFIP1, EDNRB, AKT1, POR, ADCY9, ABCB4, FPR2, SLC30A10, PRKAR2B, LYN, EGR1, EGR2, JAG1, CDC6, CD36, ARG1, AVPR1A, CEACAM1, TLR4, TLR2, PTGS2, GNAI1, SORT1, CTGF, GHSR, LHCGR, FOXO1, TGFB1, CAV1, NR4A2, NR4A1, HHEX, GRM5, GLP2R, LRP1, RETN, TSHR, KLF5, TEK, FCGR2B]
GO:0048789;cytoskeletal matrix organization at active zone;6.0;1.0;0.8231203125901445;9.628524252492122;21.934314412845083;9.777073627680469;7.341217637965568E-4;0.8231203125901445;[NLGN1]
GO:0001780;neutrophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;8.16763571524637;0.0013947181159950893;0.7408135829017477;[JAM3]
GO:0001662;behavioral fear response;5.0;1.0;0.7902410118609202;9.628524252492122;37.889479621082295;6.375876246018314;0.0012681267845998157;0.6163036195908642;[GABRA5, DRD4]
GO:0048671;negative regulation of collateral sprouting;11.0;0.8653626801206646;0.8651102923899945;9.55953138100517;1259.831068844912;7.57984905034425;0.042165412099888104;0.8200627852632958;[DCC]
GO:0048791;calcium ion-regulated exocytosis of neurotransmitter;10.0;0.8933024483968273;0.861892236059334;9.551563211355994;176.6280078189881;6.343086423195323;0.005911580466814719;0.7396267465268138;[SYT2]
GO:0002622;regulation of B cell antigen processing and presentation;8.0;0.8933024483968273;0.8216512241984136;9.485423408851448;61.46352901150543;9.777073627680469;0.0020571290024302383;0.875;[FCGR2B]
GO:0002503;peptide antigen assembly with MHC class II protein complex;7.0;1.0;0.8509193652572005;9.628524252492122;45.61567929762514;8.67846133901236;0.0015267157346454312;0.7947362817240173;[HLA-DMA, HLA-DRA]
GO:0071420;cellular response to histamine;6.0;1.0;0.8231203125901445;9.628524252492122;323.55683510166546;7.697632086000634;0.010829156088606304;0.7167775754447168;[GABRB1]
GO:0002866;positive regulation of acute inflammatory response to antigenic stimulus;9.0;0.7866048967936545;0.7895430735771163;9.423729839846109;536.1761589628609;7.8311634786251565;0.017945333513272207;0.7967266896635242;[CNR1, BTK]
GO:0071300;cellular response to retinoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;200.602279209425;5.54296712308321;0.006713977754809188;0.606587909038952;[LYN, ABCA1, MYB, EPHA3]
GO:0071421;manganese ion transmembrane transport;9.0;0.8933024483968273;0.8428918493787028;9.4949928598676;98.82364420707664;8.390779266560578;0.003307538436105251;0.8253454670833372;[SLC11A1, SLC30A10]
GO:0001657;ureteric bud development;8.0;1.0;0.875;9.628524252492122;36.921511297847346;6.139487467954083;0.0012357297559360753;0.6889736746265369;[ROBO2, TGFB1, EPCAM, SDC1]
GO:0046135;pyrimidine nucleoside catabolic process;8.0;0.7307253602413294;0.7403626801206646;9.333724712271477;1255.5710096994353;6.686031174322154;0.04202283175409332;0.7169239451870815;[CDA, NT5E, UPP1]
GO:0002506;polysaccharide assembly with MHC class II protein complex;6.0;1.0;0.8231203125901445;9.628524252492122;58.63041707748974;9.083926447120524;0.0019623072956339374;0.7876727335416686;[HLA-DRA]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[PYCARD, EDNRB, GHSR, MEF2C, SLC11A1, CD180, F2R, KMO, SLPI, ADAM9, S100A8, CD274, ABCB4, C5AR1, MGST1, LY96, CSF2RB, TNFRSF11A, STAP1, NLRP3, ELANE, ABCA1, DEFA4, TNFRSF10C, TNFRSF10B, DEFA1, SELE, ALPL, HMGB2, CXCL1, TREM2, CXCL2, CTSG, CD36, PTGIR, ARG1, PDCD1LG2, TNFRSF1B, TLR4, CEBPE, PTGS2, CNR1, NR1H2, LILRB1, LILRB2, LTBR]
GO:0032376;positive regulation of cholesterol transport;8.0;0.811012628672052;0.780506314336026;9.32314260294094;149.26567110214077;6.7325511899570465;0.004995787681406127;0.719302980950052;[ABCA1, LRP1, NR1H2, ABCB4]
GO:0015813;L-glutamate transmembrane transport;11.0;0.8653626801206646;0.8651102923899945;9.551563211355994;441.01685901872065;6.8867018697843045;0.014760437381951706;0.7846152062148197;[SLC1A3, SLC17A6, SLC7A11]
GO:0071549;cellular response to dexamethasone stimulus;9.0;1.0;0.896240625180289;9.628524252492122;704.2721689024621;6.343086423195323;0.023571355689363423;0.7206263598461826;[TGFB1, ARG1, ABCB4, FOXO1]
GO:1990839;response to endothelin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;9.083926447120524;0.0024778305216419678;0.8154717862087246;[EDNRB]
GO:0010001;glial cell differentiation;4.0;0.7192862368539868;0.6096431184269935;8.404748820870006;21.066225782797595;5.528578385631111;7.050676185779127E-4;0.5327317557463623;[FGF5, TSPAN2, GPR157, EGR2, CDKN2C, PLP1]
GO:2000302;positive regulation of synaptic vesicle exocytosis;11.0;0.8259837884571596;0.845420846558242;9.533214072687796;1061.769420372717;8.67846133901236;0.03553646696943479;0.8762458687964789;[NLGN1]
GO:0035645;enteric smooth muscle cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;23.368810875791638;9.777073627680469;7.821330694483778E-4;0.8231203125901445;[EDNRB]
GO:0034394;protein localization to cell surface;5.0;1.0;0.7902410118609202;9.628524252492122;29.829169826127035;6.686031174322154;9.983554695705216E-4;0.6321649570480018;[FLNA, PTPRK, CD177]
GO:0015871;choline transport;7.0;1.0;0.8509193652572005;9.628524252492122;80.15881372336156;7.697632086000634;0.002682843357072172;0.7445766281117727;[SLC44A5, SLC5A7, SLC44A1]
GO:0090138;regulation of actin cytoskeleton organization by cell-cell adhesion;8.0;1.0;0.875;9.628524252492122;46.024468021678764;9.777073627680469;0.0015403975253535395;0.875;[JAM3]
GO:0090251;protein localization involved in establishment of planar polarity;5.0;1.0;0.7902410118609202;9.628524252492122;29.829169826127035;9.777073627680469;9.983554695705216E-4;0.7902410118609202;[CELSR1]
GO:0043388;positive regulation of DNA binding;5.0;0.7090535922965819;0.6447678080092112;8.578702127993445;32.525455185636034;5.825829909099042;0.0010885977140540058;0.5881742243410422;[HMGB2, TGFB1, EGF, MMP9]
GO:0042059;negative regulation of epidermal growth factor receptor signaling pathway;8.0;0.8436909121759173;0.7968454560879586;9.417215158824915;234.05310184950287;6.113511981550823;0.00783354668478672;0.6876452870438905;[NUP62, EGF, HGS]
GO:0090370;negative regulation of cholesterol efflux;9.0;1.0;0.896240625180289;9.628524252492122;184.35455179279643;8.390779266560578;0.006170180940179963;0.8253454670833372;[EGF]
GO:0060842;arterial endothelial cell differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;26.39894457606027;8.390779266560578;8.835489174530868E-4;0.7800242071602487;[TMEM100]
GO:0002322;B cell proliferation involved in immune response;7.0;1.0;0.8509193652572005;9.628524252492122;134.15586607783627;8.390779266560578;0.004490076105184324;0.7800242071602487;[CD180]
GO:0000255;allantoin metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.474373572664863;115.88063467460819;8.16763571524637;0.0038784205567587364;0.7079342821725234;[GHR]
GO:0002437;inflammatory response to antigenic stimulus;5.0;0.7369933605727446;0.6587376921472925;8.866384200445225;27.85633247086267;6.343086423195323;9.323263787281718E-4;0.6146267465268138;[HMGB2, IL5RA, CXCR2, ELANE]
GO:0043031;negative regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.92306413003195;7.57984905034425;0.00424800073309046;0.738553198190834;[BPI, FCGR2B, CD200]
GO:0002316;follicular B cell differentiation;9.0;1.0;0.896240625180289;9.628524252492122;149.8071031872776;9.083926447120524;0.005013908926038414;0.8607930461318132;[FCGR2B]
GO:0045332;phospholipid translocation;8.0;1.0;0.875;9.628524252492122;116.86638763413639;6.641579411751319;0.003911412821194078;0.7146506799819907;[ABCA1, ATP8B4, ABCB4]
GO:1990963;establishment of blood-retinal barrier;4.0;1.0;0.75;9.628524252492122;32.15320660831846;9.777073627680469;0.001076138889173156;0.75;[ABCB4]
GO:0002318;myeloid progenitor cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;22.164838071467113;8.390779266560578;7.418371831928127E-4;0.7193458537639684;[JAM3]
GO:2000311;regulation of AMPA receptor activity;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;200.74624271324296;6.558197802812269;0.006718796083723233;0.7316271658034954;[MEF2C, NLGN1]
GO:2000310;regulation of NMDA receptor activity;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;200.74624271324296;6.8867018697843045;0.006718796083723233;0.7484268790654467;[MEF2C, NLGN1]
GO:0050911;detection of chemical stimulus involved in sensory perception of smell;5.0;1.0;0.7902410118609202;9.628524252492122;23.389107696328047;3.713288418992861;7.828123857657788E-4;0.48013875429378605;[OR1E1, OR1G1, OR2J2, OR2W1, OR11A1, OR12D3]
GO:0015746;citrate transport;9.0;0.8933024483968273;0.8428918493787028;9.485423408851448;69.26890205252035;7.9853141584524145;0.002318367813733332;0.8046099625986299;[SLC13A1]
GO:0055007;cardiac muscle cell differentiation;6.0;0.7866048967936545;0.7164227609869718;9.0689084645567;45.916641199513585;6.409777797693995;0.0015367886586535107;0.6509166472493662;[MEF2C, NOX4, SIK1]
GO:1905184;positive regulation of protein serine/threonine phosphatase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1090.3691173458615;9.777073627680469;0.036493673089069714;0.9324289523296623;[FCRL3]
GO:0035590;purinergic nucleotide receptor signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;27.195621953761602;6.641579411751319;9.102129923216596E-4;0.6905700452391912;[P2RY13, P2RY14, GPR87, PTAFR, P2RX5, P2RY6, P2RY2, P2RX1, GPR171]
GO:0045577;regulation of B cell differentiation;8.0;0.7369933605727446;0.7434966802863723;9.223059144383958;130.3775146173893;6.518977089658987;0.004363618082098712;0.7083807915285978;[FCRL3, NFAM1, INHBA, BTK]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[LRRK2, RUVBL1, JUP, EGF, CAV1, SULF2, LGR4]
GO:0090022;regulation of neutrophil chemotaxis;10.0;0.8933024483968273;0.861892236059334;9.517298617381897;138.915002380433;6.193554689224359;0.004649360114287637;0.731979686697602;[C5AR1, CXCL1, CXCL2, BST1, CXCR2, C3AR1, JAM3]
GO:0046425;regulation of JAK-STAT cascade;8.0;0.7586651285174919;0.754332564258746;9.158520623246385;46.16872612457469;4.77312732173501;0.0015452257142336023;0.6190979532066485;[IFNA5, IFNA4, IFNA7, IFNA2, LRRC4, PRL, IFNA8, GHR, PPP2R1A, LRRTM4, IL6R, IFNA14, IFNA16, F2R, HGS, IFNA10, LRRC19, FLRT2, IFNA21, LYN, EGF, CAV1, GH1]
GO:0048843;negative regulation of axon extension involved in axon guidance;12.0;1.0;0.9481203125901445;9.628524252492122;2931.023726508963;6.558197802812269;0.09809872637615838;0.7835068532133509;[NRP1, SEMA4B]
GO:0043278;response to morphine;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;93.3430750065417;6.280566066213989;0.0031241087171554015;0.6721078059595746;[ABCB4, TACR3, CNR1]
GO:0046426;negative regulation of JAK-STAT cascade;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;286.97803335492995;5.845247994956144;0.009604896512927369;0.6951668794741764;[LRRC19, CAV1, LRRC4, FLRT2, HGS, PPP2R1A, LRRTM4]
GO:0045580;regulation of T cell differentiation;8.0;0.5976175254657065;0.6738087627328533;8.663443356448536;131.165971977755;4.909539177224887;0.004390007040384596;0.626074061840201;[CD83, SLC46A2, IFNA2, MYB, HLA-DOA, CR1, CLPTM1, NLRP3, TGFB1, EGR3, LILRB2, CD2, VNN1, BCL6, CAMK4, CD28]
GO:0060838;lymphatic endothelial cell fate commitment;6.0;1.0;0.8231203125901445;9.628524252492122;23.73605477108207;9.777073627680469;7.944243921257006E-4;0.8231203125901445;[PDPN]
GO:0050925;negative regulation of negative chemotaxis;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;129.05825862622288;9.083926447120524;0.004319463771327681;0.8154717862087246;[ROBO2]
GO:0050804;modulation of chemical synaptic transmission;6.0;0.5214636594213398;0.5838521423008144;7.2437010612611035;27.32355736088522;3.9162874042146036;9.144948752636959E-4;0.5233994325676684;[TNR, MEF2C, CHRNB4, F2R, KMO, SLC1A3, DRD4, EGR2, PLK2, MCTP1, LRRK2, NRGN, GRM5, SORCS3, SLC24A1, NLGN1, RETN, PTGS2, GNAI1, GNAI2, CNR1, NLGN4Y, LILRB2]
GO:0035589;G-protein coupled purinergic nucleotide receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;82.06132384088221;7.069023426578259;0.0027465186585576445;0.7365101867784198;[P2RY13, P2RY6, P2RY14, P2RY2, GPR87, PTAFR, GPR171]
GO:0035584;calcium-mediated signaling using intracellular calcium source;8.0;1.0;0.875;9.628524252492122;30.117246255164275;6.781341354126479;0.0010079971283984438;0.7217981122146513;[GRM5, AZU1]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, PTGS2, CD4, ALPL]
GO:0034374;low-density lipoprotein particle remodeling;7.0;1.0;0.8509193652572005;9.628524252492122;83.38206178822108;7.212124270218933;0.0027907225690680937;0.7197477358342742;[AGTR1, PLA2G7]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[GJC1, TMEM100, HHEX, TGFB1, CAV1, PTK2, ENG]
GO:0048739;cardiac muscle fiber development;7.0;1.0;0.8509193652572005;9.628524252492122;104.2020218467692;7.004484905440688;0.003487547895480139;0.7091290490632969;[CXADR]
GO:0099054;presynapse assembly;4.0;1.0;0.75;9.628524252492122;34.5996765512564;7.474488534686424;0.0011580200364832854;0.6322456912631272;[NLGN4Y, NLGN1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, EDNRB, PCBP3, EGR1, BCL11A, XPO1, CD36, CCNE1, TGFB1, CBX4, CAV1, NR4A2, MXD1, FBP1, MEIS2]
GO:0045471;response to ethanol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;69.73224034292265;5.006389003214805;0.0023338753293357085;0.5462679783062231;[CLDN3, CLDN7, S100A8, CNR1, GSN]
GO:0043171;peptide catabolic process;6.0;0.7192862368539868;0.682763431017138;8.971744716103052;139.83704318034597;6.280566066213989;0.0046802199900778775;0.6443087532925187;[ACE, TRHDE, ANPEP]
GO:0045475;locomotor rhythm;4.0;1.0;0.75;9.628524252492122;28.705510431398622;7.474488534686424;9.607476008567623E-4;0.6322456912631272;[MC3R, KCND2]
GO:2000573;positive regulation of DNA biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;748.2879117532506;5.618190544320798;0.02504452299098255;0.6623145257091445;[RFC5, RFC3, RFC4, RFC2, NOX4]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRR, PTPRK, DUSP2, DUSP1, DUSP6, TPTE, PTPRE]
GO:0050707;regulation of cytokine secretion;8.0;0.5887823193610073;0.6693911596805037;8.358061706897352;114.42085987655861;4.647174912757396;0.003829563207980042;0.6126567411541474;[PYCARD, CLEC5A, GHSR, IL1R2, F2R, CD274, NLRP3, LYN, FZD5, ORM1, LRRK2, IFNA2, FFAR2, IL17RB, MMP12, TLR1, BANK1, IGHD, TLR8, TLR10, TLR5, TLR4, TLR2, CD58, LILRB1, CD2, NLRP12, FCGR2B, LGR4]
GO:0060856;establishment of blood-brain barrier;4.0;0.8933024483968273;0.6966512241984136;9.34084218004034;32.15320660831846;8.390779266560578;0.001076138889173156;0.6791048419030481;[ABCB4, LSR]
GO:0001580;detection of chemical stimulus involved in sensory perception of bitter taste;6.0;1.0;0.8231203125901445;9.628524252492122;24.998545608763582;6.063501560976162;8.36678824294913E-4;0.6332080644001243;[TAS2R7, TAS2R10, TAS2R13]
GO:0045597;positive regulation of cell differentiation;5.0;0.4493394816318884;0.5149107526768645;6.573475401781711;82.53300662006848;2.970244267288293;0.0027623054566900678;0.44213944182052767;[CYFIP1, MYB, AKT1, MEF2C, SPINT1, AGTR1, SFN, LYN, JAG1, EZH2, ENG, PTGS2, FLNA, PLXND1, CTGF, CDH5, OLFM4, TACSTD2, BCL6, ADAMTS20, NLGN1, KLF5, CPNE5, RUNX2, BTC, POR, BTK, EPHA3, CCR1, MSR1, EGR3, VNN1, CD24, ROBO2, NRP1, CD36, CCR2, CEACAM1, TLR2, CXCR4, PDPN, LILRB2, SCARB2, CD83, IL6R, LTBP3, NLRP3, TGFB1, SYT2, INHBA, TCF4, DOCK5, HMGB2, TMEM100, DNM2, LTF, CNR1, CD4, ACIN1]
GO:1901731;positive regulation of platelet aggregation;10.0;0.9326813400603323;0.8815816818910864;9.600353375525426;486.3301511218916;9.083926447120524;0.016277032489329563;0.8797934328124444;[PDPN]
GO:0002430;complement receptor mediated signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.57973408832269;218.73839564357212;7.212124270218933;0.007320977250414979;0.7650689957573628;[CR2, CR1, C5AR1, FPR1, C3AR1, FPR3, FPR2]
GO:0046449;creatinine metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.5544162803384;104.72312179279828;8.390779266560578;0.0035049886417142283;0.7522251544931926;[GHR, MME]
GO:0001696;gastric acid secretion;6.0;0.8653626801206646;0.7558016526504768;9.34084218004034;27.793112993610514;7.8311634786251565;9.302104797183778E-4;0.7236063770733796;[SLC26A7]
GO:1902938;regulation of intracellular calcium activated chloride channel activity;9.0;0.8933024483968273;0.8428918493787028;9.517298617381897;199.08006120767874;8.67846133901236;0.006663030488198;0.8400575416471059;[GRM5]
GO:0002305;CD8-positive, gamma-delta intraepithelial T cell differentiation;9.0;1.0;0.896240625180289;9.628524252492122;91.12402004725458;9.083926447120524;0.0030498389446878675;0.8607930461318132;[CCR9, GPR18]
GO:0006906;vesicle fusion;6.0;0.6799073451904818;0.6630739851853854;8.563813515499694;63.097974703971886;5.192106149009898;0.0021118324288514666;0.5886448625081389;[DYSF, STX11, SYT2]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, SLC30A10, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, DUSP1, ANXA5, PTGS2, UNG, FLNA, GABRA5, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, BCL6, LRRK2, TNFRSF1B, ADAMTS20, LRP1, NLRC4, SLC46A2, LGALS3, TCL1A, EDNRB, BTC, POR, EPHA3, EGR3, BCL11B, PTK2, VNN1, CD28, NRP1, CEACAM6, GNAI2, CXCR2, PDPN, LILRB1, GRINA, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF, TEK]
GO:0046330;positive regulation of JNK cascade;12.0;0.8436909121759173;0.8699657686781033;9.567899630675686;1762.0380321839782;4.909539177224887;0.058973827205923174;0.6991943744303455;[CTGF, PYCARD, MAP4K1, TNFRSF11A, FZD5, PKN1, LTBR, FCGR2B]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, TNFRSF10B, BCL6, NLRC4, P2RX1, PPP2R1A, SIK1, TNFSF12, ITM2C, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, NLRP3, TGFB1, CAV1, INHBA, UBE2M, MMP9, DNM2, CNR1, LTBR]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[NCF4, CD36, CD93, ANXA3, SLC11A1, DNM2, PECAM1, PRTN3, CD302, LRP1, CEBPE, PLD4, CORO1A, ELANE, MARCO]
GO:0034599;cellular response to oxidative stress;4.0;0.7248374789738407;0.6124187394869203;8.935377071932177;68.67201153720991;4.519578255652688;0.0022983904253524798;0.48113144217596127;[IL18RAP, MYB, AKT1, BTK, MGST1, FOXO1, NR4A2, NOX4, EZH2, LRRK2, PTPRK, CD36, ARG1, MMP9, DNM2, PCNA]
GO:2000463;positive regulation of excitatory postsynaptic potential;8.0;0.9326813400603323;0.8413406700301662;9.589303539338841;397.97278468673557;6.518977089658987;0.013319790951212034;0.7083807915285978;[NLGN1]
